

1 RICHARD B. GOETZ (S.B. #115666)  
2 rgoetz@omm.com  
3 ROBERT M. SWERDLOW (S.B. #200266)  
4 rswerdlow@omm.com  
5 O'MELVENY & MYERS LLP  
6 400 South Hope Street  
7 Los Angeles, California 90071-2899  
8 Telephone: (213) 430-6000  
9 Facsimile: (213) 430-6407

10 MATTHEW D. POWERS (S.B. #212682)  
11 mpowers@omm.com  
12 JILLIAN SOMERS (S.B. # 267544)  
13 jsomers@omm.com  
14 O'MELVENY & MYERS LLP  
15 Two Embarcadero Center, 28th Floor  
16 San Francisco, CA 94111-3823  
17 Telephone: (415) 984-8700  
18 Facsimile: (415) 984-8701

19 Attorneys for Defendant  
20 Neutrogena Corporation

21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
CENTRAL DISTRICT OF CALIFORNIA  
WESTERN DIVISION

MARA CHOW, individually and on  
behalf of all others similarly situated,

Plaintiff,

vs.

NEUTROGENA CORP., a Delaware  
Corporation; and DOES 1 through 100,  
inclusive,

Defendants.

Case No. CV 12-04624 R (JCx)

**NEUTROGENA'S OPPOSITION  
TO PLAINTIFF'S MOTION FOR  
CLASS CERTIFICATION**

Hearing Date: November 19, 2012  
Hearing time: 10:00 a.m.  
Courtroom: 8

Pretrial Conference: Not set  
Trial Date: Not set

## TABLE OF CONTENTS

	<b>Page</b>
I. INTRODUCTION.....	1
II. BACKGROUND FACTS .....	2
A. The Six Products at Issue.....	2
B. Retinol .....	3
C. Independently Conducted Scientific Studies Confirm That the Products Deliver Benefits for Many Consumers .....	3
D. Different Consumers Have Different Reactions to Retinol .....	5
E. Different Messages Were Used to Promote the Products.....	5
F. Most of These Products Are Sold to Repeat Purchasers .....	6
G. The National Advertising Division's Report.....	7
III. PLAINTIFF HAS FAILED TO MEET HER EVIDENTIARY BURDEN TO SHOW THAT RULE 23'S REQUIREMENTS ARE SATISFIED .....	7
IV. STATE LAW VARIATIONS PRECLUDE CERTIFICATION OF A NATIONWIDE UNDER RULE 23(B)(2) OR (B)(3) .....	10
A. A Class Cannot Be Certified Where the Claims of Putative Class Members Must Be Assessed Under the Laws of Multiple States.....	11
B. California's "Governmental Interest" Test Requires the Application of the Law of Each Consumer's State of Purchase.....	12
1. Different States' Laws Vary in Material Ways .....	12
2. Each State Has a Strong Interest in Applying Its Own Laws.....	16
3. Other States' Interests Would Be Impaired.....	16
4. District Court Decisions Following Mazza .....	17
V. PLAINTIFF'S 23(B)(2) CLASS FAILS.....	18
VI. PLAINTIFF'S 23(B)(3) CLASS FAILS BECAUSE COMMON ISSUES DO NOT PREDOMINATE OVER INDIVIDUALIZED ISSUES.....	21
A. Each Cause of Action Requires Proof of Causation or Reliance .....	23
B. Whether Any Consumer Was Injured Is An Individualized Issue .....	24
C. Plaintiff Cannot Show Economic Injury Using Class-Wide Proof .....	27
D. Different Class Members Were Exposed to Different Messages .....	28
E. An Inference of Reliance or Materiality Would Be Inappropriate .....	31
VII. PLAINTIFF'S PROPOSED CLASS SUFFERS FROM A HOST OF OTHER PROBLEMS.....	32
VIII. PLAINTIFF CHOW IS NOT TYPICAL OR ADEQUATE .....	34
IX. CONCLUSION .....	35

1 TABLE OF AUTHORITIES  
2

	Page
3 <b>CASES</b>	
4 <i>Agostino v. Quest Diagnostics Inc.</i> , 5 256 F.R.D. 437 (D.N.J. 2009) .....	11
6 <i>Akkerman v. Mecta Corp.</i> , 7 152 Cal. App. 4th 1094 (2007) .....	22, 33
8 <i>Antoninetti v. Chipotle Mexican Grill, Inc.</i> , 9 2012 WL 3762440 (S.D. Cal. Aug. 28, 2012) .....	22
10 <i>Arnold v. United Artists Theatre Circuit, Inc.</i> , 11 158 F.R.D. 439 (N.D. Cal. 1994) .....	19
12 <i>Baby Neal ex rel. Kanter v. Casey</i> , 13 43 F.3d 48 (3d Cir. 1994) .....	19
14 <i>Baranco, Inc. v. Bardshaw</i> , 15 456 S.E.2d 592 (Ga. App. 1995) .....	13
16 <i>Baughn v. Honda Motor Co.</i> , 17 727 P.2d 655 (Wash. 1986) .....	14
18 <i>Block v. Abbott Labs.</i> , 19 2002 WL 485364 (N.D. Ill. Mar. 29, 2002) .....	12
20 <i>Block v. Major League Baseball</i> , 21 65 Cal. App. 4th 538 (1998) .....	28
22 <i>Bolin v. Sears, Roebuck &amp; Co.</i> , 23 231 F.3d 970 (5th Cir. 2000) .....	21
24 <i>Bonlender v. Am. Honda Motor Co.</i> , 25 286 F. Appx. 414 (9th Cir. 2008) .....	11
26 <i>Boucher v. First Am. Title Ins. Co.</i> , 27 2012 WL 3023316, No. C10-199RAJ (W.D. Wash. July 24, 2012) .....	10
28 <i>Broussard v. Meineke Discount Muffler Shops, Inc.</i> , 29 155 F.3d 331 (4th Cir. 1998) .....	33
30 <i>Brownfield v. Bayer Corp.</i> , 31 2009 U.S. Dist. LEXIS 63057 (E.D. Cal. July 2, 2009) .....	23
32 <i>Bruno v. Eckhart Corp.</i> , 33 280 F.R.D. 540 (C.D. Cal. 2012) .....	18

## TABLE OF AUTHORITIES (continued)

Page	
2	<i>Cambridge Lane, LLC v. J-M Manufacturing Co.</i> , 2012 U.S. Dist. LEXIS 43533 (C.D. Cal. Mar. 15, 2012) ..... 18
3	
4	<i>Campion v. Old Republic Home Prot. Co.</i> , 272 F.R.D. 517 (S.D. Cal. 2011) ..... <i>passim</i>
5	
6	<i>Caro v. Proctor &amp; Gamble Co.</i> , 18 Cal. App. 4th 644 (1993) ..... 32
7	
8	<i>Carrea v. Dreyer's Grand Ice Cream, Inc.</i> , 2011 WL 159380 (N.D. Cal. Jan. 10, 2011), <i>aff'd on other grounds</i> , 2012 WL 1131526 (9th Cir. Apr. 5, 2012) ..... 35
9	
10	<i>Cattie v. Wal-Mart Stores, Inc.</i> , 504 F. Supp. 2d 939 (S.D. Cal. 2007) ..... 23
11	
12	<i>Cholakyan v. Mercedes-Benz USA, LLC</i> , 281 F.R.D. 534 (C.D. Cal. 2012) ..... 8, 19, 20, 21
13	
14	<i>Cipollone v. Liggett Grp., Inc.</i> , 893 F.2d 541 (3d Cir. 1990), <i>aff'd in part &amp; rev'd in part</i> , 505 U.S. 504 (1992) ..... 15
15	
16	<i>City of San Jose v. Superior Court</i> , 12 Cal. 3d 447 (1974) ..... 33
17	
18	<i>Clay v. Am. Tobacco Co.</i> , 188 F.R.D. 483 (S.D. Ill. 1999) ..... 12
19	
20	<i>Cohen v. DIRECTV, Inc.</i> , 178 Cal. App. 4th 966 (2009) ..... <i>passim</i>
21	
22	<i>Colgan v. Leatherman Tool Grp., Inc.</i> , 135 Cal. App. 4th 663 (2006) ..... 27, 28
23	
24	<i>Colpinto v. Esquire Deposition Servs.</i> , 2011 WL 913251 (C.D. Cal. Mar. 8, 2011) ..... 33
25	
26	<i>Cortez v. Purolator Air Filtration Prods. Co.</i> , 23 Cal. 4th 163 (2000) ..... 27
27	
28	<i>Crawford v. Honig</i> , 37 F.3d 485 (9th Cir. 1994) ..... 21
29	
30	<i>DaimlerChrysler Corp. v. Cuno</i> , 547 U.S. 332 (2006) ..... 35
31	

## TABLE OF AUTHORITIES (continued)

Page	
2	<i>Daughtrey v. Ashe</i> , 413 S.E.2d 336 (Va. 1992).....
4	<i>Davis v. Powertel, Inc.</i> , 776 So. 2d 971 (Fla. App. 2000) .....
6	<i>Debbs v. Chrysler Corp.</i> , 810 A.2d 137 (Pa. Super. 2002) .....
8	<i>Doninger v. Pac. Nw. Bell, Inc.</i> , 564 F.2d 1304 (9th Cir. 1977).....
10	<i>Drimmer v. WD-40 Co.</i> , 2007 WL 2456003 (S.D. Cal. Aug. 24, 2007) .....
11	<i>Edgar v. MITE Corp.</i> , 457 U.S. 624, 102 S. Ct. 2629, 73 L. Ed. 2d 269 (1982) .....
13	<i>Edwards v. First Am. Corp.</i> , 251 F.R.D. 449 (C.D. Cal. 2007) .....
14	<i>Eisen v. Carlisle &amp; Jacqueline</i> , 417 U.S. 156 (1974) .....
16	<i>Ellis v. Costco Wholesale Corp.</i> , 657 F.3d 970 (9th Cir. 2011) .....
17	<i>Feitelberg v. Credit Suisse First Boston, LLC</i> , 134 Cal. App. 4th 997 (2006) .....
19	<i>Fieldstone Co. v. Briggs Plumbing Prods., Inc.</i> , 54 Cal. App. 4th 357 (1997).....
21	<i>Fischer v. Mead Johnson Labs</i> , 341 N.Y.S.2d 257 (N.Y.A.D. 1973).....
23	<i>Flory v. Silvercrest Indus. Inc.</i> , 633 P.2d 383 (Ariz. 1981).....
24	<i>Ford Motor Co. v. Sperau</i> , 708 So. 2d 111 (Ala. 1997) .....
25	<i>Friends of the Earth, Inc. v. Laidlaw Env'tl. Servs., Inc.</i> , 528 U.S. 167 (2000) .....

## TABLE OF AUTHORITIES (continued)

Page	
2	<i>Gartin v. S &amp; M NuTec LLC</i> , 245 F.R.D. 429 (C.D. Cal. 2007) .....
3	8
4	<i>Gen. Tel. Co. of Sw. v. Falcon</i> , 457 U.S. 147, 102 S. Ct. 2364, 72 L. Ed. 2d 740 (1982) .....
5	8, 22, 34
6	<i>Gianino v. Alacer Corp.</i> , 2012 U.S. Dist. LEXIS 32261 (C.D. Cal. Feb. 27, 2012).....
7	13, 17
8	<i>Gonzales v. Comcast Corp.</i> , 2012 WL 10621 (E.D. Cal. Jan. 3, 2012).....
9	32, 33
10	<i>Gonzalez v. Proctor &amp; Gamble Co.</i> , 247 F.R.D. 616 (S.D. Cal. 2007).....
11	19, 21, 31
12	<i>Granberry v. Islay Invs.</i> , 9 Cal. 4th 738 (1995).....
13	32, 33
14	<i>Halprin v. Ford Motor Co.</i> , 420 S.E.2d 686 (N.C. App. 1992) .....
15	15
16	<i>Hanon v. Dataproducts Corp.</i> , 976 F.2d 497 (9th Cir. 1992).....
17	34
18	<i>Harbor Point Homeowners' Ass'n, Inc. ex rel. Bd. of Dirs. v. DJF Enters., Inc.</i> , 697 S.E.2d 439 (N.C. App. 2010) .....
19	15
20	<i>Horowitz v. Stryker Corp.</i> , 613 F. Supp. 2d 271 (E.D.N.Y. 2009).....
21	15
22	<i>Horvath v. LG Elecs. Mobilecomm U.S.A., Inc.</i> , 2012 U.S. Dist. LEXIS 19215 (S.D. Cal. Feb. 13, 2012) .....
23	18
24	<i>Howell v. Midway Holdings, Inc.</i> , 362 F. Supp. 2d 1158 (D. Ariz. 2005).....
25	14
26	<i>Hunter v. Croysdill</i> , 169 Cal. App. 2d 307 (1959).....
27	33
28	<i>In re Bridgestone/Firestone Tire Prods. Liab. Litig.</i> , 288 F.3d 1012 (7th Cir. 2002).....
29	passim
30	<i>In re Flash Memory Antitrust Litig.</i> , 2010 WL 2332081 (N.D. Cal. June 9, 2010) .....
31	27

## TABLE OF AUTHORITIES (continued)

Page	
2	<i>In re Google Adwords Litig.</i> , 2012 WL 28068 (N.D. Cal. Jan. 5, 2012) ..... 25, 26, 27, 28
4	<i>In re Hitachi Television Optical Block Cases</i> , 2011 WL 9403 (S.D. Cal. Jan. 3, 2011) ..... 13
6	<i>In re Hydrogen Peroxide Antitrust Litig.</i> , 552 F.3d 305 (3d Cir. 2008) ..... 8
8	<i>In re Intel Corp. Microprocessor Antitrust Litig.</i> , 2010 WL 8591815 (July 28, 2010) ..... 32
10	<i>In re Paxil Litig.</i> , 218 F.R.D. 242 (C.D. Cal. 2003) ..... 21
12	<i>In re St. Jude Med., Inc.</i> , 425 F.3d 1116 (8th Cir. 2005) ..... 13
14	<i>In re Tobacco II</i> , 46 Cal. 4th 298 (2009) ..... 13, 23, 24, 26
16	<i>In re Vioxx Class Cases</i> , 180 Cal. App. 4th 116 (2009) ..... 23, 31, 32
18	<i>In re Yasmin &amp; Yaz (Drospirenone) Mktg., Sales Pract. &amp; Prod. Liab. Litig.</i> , 2012 WL 865041 (S.D. Ill. Mar. 13, 2012) ..... 26, 27
20	<i>Izzarelli v. R.J. Reynolds Tobacco Co.</i> , 117 F. Supp. 2d 167 (D. Conn. 2000) ..... 14
22	<i>Johns v. Bayer Corp.</i> , 2010 WL 476688 (S.D. Cal. Feb. 9, 2010) ..... 35
24	<i>Kaldenbach v. Mut. of Omaha Life Ins. Co.</i> , 178 Cal. App. 4th 830 (2009) ..... 28, 30, 31
26	<i>Kamar v. RadioShack Corp.</i> , 375 Fed. Appx. 734 (9th Cir. 2010) ..... 10
28	<i>Keegan v. Am. Honda Motor Co.</i> , 2012 WL 2250040 (C.D. Cal. June 12, 2012) ..... 12, 13, 14, 15
30	<i>Korea Supply Co. v. Lockheed Martin Corp.</i> , 29 Cal. 4th 1134 (2003) ..... 27

## TABLE OF AUTHORITIES (continued)

Page		
2	<i>Kuehn v. Stanley</i> , 91 P.3d 346 (Ariz. App. 2004) .....	13
4		
5	<i>Lafayette Stabilizer Repair, Inc. v. Mach. Wholesalers Corp.</i> , 750 F.2d 1290 (5th Cir. 1985).....	15
6		
7	<i>Lanzarone v. Guardsmark Holdings, Inc.</i> , 2006 WL 4393465 (C.D. Cal. Sept. 7, 2006).....	22
8		
9	<i>Larsen v. Trader Joe's Co.</i> , No. 3:11-cv-05188-SI (N.D. Cal. June 14, 2012) .....	35
10		
11	<i>LeClercq v. Michael</i> , 88 Cal. App. 2d 700 (1948).....	33
12		
13	<i>Lozano v. AT&amp;T Wireless Servs., Inc.</i> , 504 F.3d 718 (9th Cir. 2007).....	19, 21
14		
15	<i>Lujan v. Defenders of Wildlife</i> , 504 U.S. 555 (1992) .....	35
16		
17	<i>Mahfood v. QVC, Inc.</i> , 2008 WL 5381088 (Sept. 22, 2008) .....	27
18		
19	<i>Mass. Mut. Life Ins. Co. v. Superior Court</i> , 97 Cal. App. 4th 1282 (2002).....	23, 31
20		
21	<i>Maybank v. S.S. Kresge Co.</i> , 273 S.E.2d 681 (N.C. 1981) .....	15
22		
23	<i>Mazur v. eBay Inc.</i> , 257 F.R.D. 563 (N.D. Cal. 2009) .....	27, 33
24		
25	<i>Mazza v. American Honda Motor Co.</i> , 666 F.3d 581 (9th Cir. 2012) .....	passim
26		
27	<i>McCann v. Foster Wheeler LLC</i> , 48 Cal. 4 <sup>th</sup> 68 (Cal. 2010) .....	17
28		
29	<i>Mlejneky v. Olympus Imaging Am., Inc.</i> , 2011 WL 1497096 (E.D. Cal. Apr. 19, 2011).....	35
30		
31	<i>Moncada v. Allstate Ins. Co.</i> , 471 F. Supp. 2d 987 (N.D. Cal. 2006).....	23, 28
32		

## TABLE OF AUTHORITIES (continued)

Page	
2	<i>Nat'l Council Against Health Fraud, Inc. v. King Bio Pharm., Inc.</i> , 107 Cal. App. 4th 1336 (2003).....9
4	<i>Occidental Land v. Superior Court</i> , 18 Cal. 3d 355 (Cal. 1976) .....31
6	<i>Offshore Rental Co. v. Cont'l Oil Co.</i> , 583 P.2d 721 (Cal. 1978).....17
8	<i>P &amp; F Constr. Corp. v. Friend Lumber Corp.</i> , 575 N.E.2d 61 (Mass. App. Ct. 1991).....15
10	<i>Petersen v. Talisman Sugar Corp.</i> , 478 F.2d 73 (5th Cir. 1973).....19
11	<i>Pfizer, Inc. v. Superior Court</i> , 182 Cal. App. 4th 622 (2010).....28, 30, 31
13	<i>Quezada v. Loan Ctr. of Cal., Inc.</i> , 2009 WL 5113506 (E.D. Cal. 2009).....32
14	<i>Randleman v. Fidelity Nat. Title Ins. Co.</i> , 646 F.3d 347 (6th Cir. 2011).....10
16	<i>Rikos v. Procter &amp; Gamble Co.</i> , 2012 WL 641946 (S.D. Ohio Feb. 28, 2012).....14
17	<i>Riley v. Nev. Supreme Court</i> , 763 F. Supp. 446 (D. Nev. 1991) .....19
19	<i>Sanders v. Apple, Inc.</i> , 672 F. Supp. 2d 978 (N.D. Cal. 2009).....15, 24
21	<i>Sanders v. Johnson &amp; Johnson, Inc.</i> , 2006 U.S. Dist. LEXIS 35881 (D.N.J. May 31, 2006) .....12
23	<i>Seaside Resorts, Inc. v. Club Car, Inc.</i> , 416 S.E.2d 655 (S.C. App. 1992).....15
24	<i>Sebago, Inc. v. Beazer E., Inc.</i> , 18 F. Supp. 2d 70 (D. Mass. 1998).....14
26	<i>Sevidal v. Target Corp.</i> , 189 Cal. App. 4th 905 (2010).....24, 28, 30

## TABLE OF AUTHORITIES (continued)

Page	
2	<i>Slaven v. BP Am., Inc.</i> , 190 F.R.D. 649 (C.D. Cal. 2000) ..... 22
3	
4	<i>Spence v. Glock, Ges.m.b.H.</i> , 227 F.3d 308 (5th Cir. 2000) ..... 16
5	
6	<i>Stanley v. Bayer Healthcare LLC</i> , 2012 WL 1132920 (S.D. Cal. Apr. 3, 2012) ..... 9
7	
8	<i>Stearns v. Select Comfort Retail Corp.</i> , 763 F. Supp. 2d 1128 (N.D. Cal. 2010) ..... 15
9	
10	<i>Stephenson v. Capano Dev., Inc.</i> , 462 A.2d 1069 (Del. 1983) ..... 14
11	
12	<i>Sterns v. Ticketmasters Corp.</i> , 655 F.3d 1013 (9th Cir. 2011) ..... 26
13	
14	<i>Steroid Hormone Prod. Cases</i> , 181 Cal. App. 4th 145 (2010) ..... 31
15	
16	<i>Stutman v. Chem. Bank</i> , 731 N.E.2d 608 (N.Y. 2000) ..... 14
17	
18	<i>Suzuki v. Hitachi Global Storage Techs., Inc.</i> , 2007 U.S. Dist. LEXIS 51605 (N.D. Cal. July 16, 2007) ..... 23
19	
20	<i>Szabo v. Bridgeport Machs., Inc.</i> , 249 F.3d 672 (7th Cir. 2001) ..... 8
21	
22	<i>Teamsters Local 445 v. Bombardier, Inc.</i> , 546 F.3d 196 (2d Cir. 2008) ..... 8
23	
24	<i>Tucker v. Pac. Bell Mobile Servs.</i> , 208 Cal. App. 4th 201 (2012) ..... 24, 25, 31
25	
26	<i>Util. Consumers' Action Network v. Sprint</i> , 259 F.R.D. 484 (S.D. Cal. 2009) ..... 20
27	
28	<i>Valente v. Sofamor, S.N.C.</i> , 48 F. Supp. 2d 862 (E.D. Wis. 1999) ..... 13
29	
30	<i>Vasquez v. Superior Court</i> , 4 Cal. 3d 800 (Cal. 1971) ..... 31, 32
31	

## TABLE OF AUTHORITIES (continued)

2	(continued)	Page
3	<i>Wal-Mart Stores, Inc. v. Dukes</i> , 131 S. Ct. 2541, 180 L. Ed. 2d 374 (2011) .....	passim
4		
5	<i>Wash. Mut. Bank v. Superior Court</i> , 24 Cal. 4th 906 (2001).....	12, 16, 17
6		
7	<i>Weinstat v. Dentsply Int'l, Inc.</i> , 180 Cal. App. 4th 1213 (2010).....	14, 23
8		
9	<i>Wilens v. TD Waterhouse Grp., Inc.</i> , 120 Cal. App. 4th 746 (2003).....	24, 28
10		
11	<i>Williams v. Beechnut Nutrition</i> , 185 Cal. App. 3d 135 (1986) .....	23, 28
12		
13	<i>Williams v. Oberon Media, Inc.</i> , 2010 WL 8453723 (C.D. Cal. April 19, 2010) .....	22
14		
15	<i>Zachery v. Texaco Exploration &amp; Prods.</i> , 185 F.R.D. 230 (W.D. Tex. 1999).....	21
16		
17	<i>Zinser v. Accufix Research Inst., Inc.</i> , 253 F.3d 1180 (9th Cir. 2001).....	passim
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		
65		
66		
67		
68		
69		
70		
71		
72		
73		
74		
75		
76		
77		
78		
79		
80		
81		
82		
83		
84		
85		
86		
87		
88		
89		
90		
91		
92		
93		
94		
95		
96		
97		
98		
99		
100		
101		
102		
103		
104		
105		
106		
107		
108		
109		
110		
111		
112		
113		
114		
115		
116		
117		
118		
119		
120		
121		
122		
123		
124		
125		
126		
127		
128		
129		
130		
131		
132		
133		
134		
135		
136		
137		
138		
139		
140		
141		
142		
143		
144		
145		
146		
147		
148		
149		
150		
151		
152		
153		
154		
155		
156		
157		
158		
159		
160		
161		
162		
163		
164		
165		
166		
167		
168		
169		
170		
171		
172		
173		
174		
175		
176		
177		
178		
179		
180		
181		
182		
183		
184		
185		
186		
187		
188		
189		
190		
191		
192		
193		
194		
195		
196		
197		
198		
199		
200		
201		
202		
203		
204		
205		
206		
207		
208		
209		
210		
211		
212		
213		
214		
215		
216		
217		
218		
219		
220		
221		
222		
223		
224		
225		
226		
227		
228		
229		
230		
231		
232		
233		
234		
235		
236		
237		
238		
239		
240		
241		
242		
243		
244		
245		
246		
247		
248		
249		
250		
251		
252		
253		
254		
255		
256		
257		
258		
259		
260		
261		
262		
263		
264		
265		
266		
267		
268		
269		
270		
271		
272		
273		
274		
275		
276		
277		
278		
279		
280		
281		
282		
283		
284		
285		
286		
287		
288		
289		
290		
291		
292		
293		
294		
295		
296		
297		
298		
299		
300		
301		
302		
303		
304		
305		
306		
307		
308		
309		
310		
311		
312		
313		
314		
315		
316		
317		
318		
319		
320		
321		
322		
323		
324		
325		
326		
327		
328		
329		
330		
331		
332		
333		
334		
335		
336		
337		
338		
339		
340		
341		
342		
343		
344		
345		
346		
347		
348		
349		
350		
351		
352		
353		
354		
355		
356		
357		
358		
359		
360		
361		
362		
363		
364		
365		
366		
367		
368		
369		
370		
371		
372		
373		
374		
375		
376		
377		
378		
379		
380		
381		
382		
383		
384		
385		
386		
387		
388		
389		
390		
391		
392		
393		
394		
395		
396		
397		
398		
399		
400		
401		
402		
403		
404		
405		
406		
407		
408		
409		
410		
411		
412		
413		
414		
415		
416		
417		
418		
419		
420		
421		
422		
423		
424		
425		
426		
427		
428		
429		
430		
431		
432		
433		
434		
435		
436		
437		
438		
439		
440		
441		
442		

## TABLE OF AUTHORITIES (continued)

Page		
2	Cal. Com. Code § 2313(1)(a) .....	23
4	Cal. Com. Code § 2313, U.C.C. cmt. 3 .....	14
5	Colo. Rev. Stat. § 6-1-105(1)(e), (g), (u).....	13
6	Colo. Rev. Stat. Ann. §§ 6-1-113(2)(a).....	14
7	Ga. Code Ann. § 10-1-399.....	13
8	Ind. Code Ann. § 24-5-05-4(a).....	13
9	La. Rev. Stat. Ann. § 51:1409(A).....	13
10	Mich. Comp. Laws Ann. § 445-905(1) .....	14
11	Miss. Code Ann. § 75-24-15(4).....	13
12	Miss. Code Ann. § 78-24-15(1).....	14
13	N.C. Gen. Stat. § 25-2-313 cmt. 3 .....	15
14	N.J. Stat. Ann. § 56:8-2 .....	13
15	N.M. Stat. Ann. § 57-12-10(E).....	14
16	Ohio Rev. Code Ann. § 1345-09(A)(B) .....	14
17	Or. Rev. Stat. § 6469-638(6) .....	13
18	R.I. Gen. Laws § 9-1-13 .....	13
19	S.D. Codified Laws § 37-24-31.....	14
20	Va. Code Ann. § 59.1-204.1(A) .....	13
21	<b><u>OTHER AUTHORITIES</u></b>	
22	Manual for Complex Litigation (4th ed.) .....	19
23	Restatement (Second) of Conflict of Laws § 148 .....	17
24	S. Rep. No. 109-14 (2005).....	16
25	<b><u>RULES</u></b>	
26	Fed. R. Civ. P. 23 .....	1, 7, 8

## TABLE OF AUTHORITIES (continued)

2	(continued)	Page
3	Fed. R. Civ. P. 23(a) .....	21
4	Fed. R. Civ. P. 23(a)(2).....	9
5	Fed. R. Civ. P. 23(b).....	11
6	Fed. R. Civ. P. 23(b)(2) .....	11, 18, 19, 21
7	Fed. R. Civ. P. 23(b)(2) Advisory Comm. Notes (1966 Amendments).....	11
8	Fed. R. Civ. P. 23(b)(3) .....	11, 19, 21, 33
9	Fed. R. Civ. P. 23(b)(3)(D).....	34

1       **I. INTRODUCTION**

2       This supposedly “straightforward false advertising case” is anything but.  
 3 Plaintiff’s motion must be denied because she is wrong on the facts, wrong on the  
 4 law, and has failed to satisfy her burden under Rule 23. In an effort to avoid  
 5 proving that individual issues do not predominate, Plaintiff takes extreme legal and  
 6 factual positions that are unsupported by any evidence. Retinol and retinoids have  
 7 been studied for *decades*; their benefits in reducing the visible signs of aging in skin  
 8 are well-established. Double-blind clinical studies on these very products  
 9 (Neutrogena’s Healthy Skin Anti-Wrinkle (“HSAW”) and Rapid Wrinkle Repair  
 10 (“RWR”) products) show they can provide substantial benefits. Yet Plaintiff’s  
 11 entire motion rests on bare assertions—supported only by allegations—that no  
 12 “scientific studies ‘prove’ the efficacy of retinol” and that every user “suffered a  
 13 common injury” by “paying for a worthless product.” (Mot. at 1, 8.)

14       “Rule 23 does not set forth a mere pleading standard. A party seeking class  
 15 certification must affirmatively demonstrate his compliance with the Rule—that is,  
 16 he must be prepared to prove that there are *in fact* sufficiently numerous parties,  
 17 common questions of law or fact, etc.” *Wal-Mart Stores, Inc. v. Dukes*, 131 S. Ct.  
 18 2541, 2551 (2011). Plaintiff has not done so. She never identifies the common  
 19 evidence she will use to prove her class claims—much less evidence proving the  
 20 requirements of Rule 23 are satisfied—and several key arguments in her motion  
 21 rely on mere allegations. Her motion should be denied on that basis alone.

22       Plaintiff’s motion also suffers from a host of legal and factual problems that  
 23 preclude certification of any of her proposed classes. Although Plaintiff seeks to  
 24 apply California law to a nationwide class, she fails even to mention the Ninth  
 25 Circuit’s holding in *Mazza v. American Honda Motor Co.*, 666 F.3d 581 (9th Cir.  
 26 2012) that “each class member’s consumer protection claim should be governed by  
 27 the consumer protection laws of the jurisdiction in which the transaction took  
 28 place.” *Id.* at 594. A nationwide class is thus unworkable and must be rejected,

1 and her Rule 23(b)(2) class also fails—monetary relief is hardly “incidental” here.

2 Equally important, Plaintiff’s asserted predominance of “common issues”  
 3 ignores the practical reality of any trial on her claims. These claims cannot be  
 4 proven on a class-wide basis and individual issues will overwhelmingly  
 5 predominate. Consumers buy these products because of their **visible** benefits.  
 6 Thus, anyone who uses the products knows *exactly* what benefits they provide.

7 **Redacted**

8 (See Declaration of Jennifer Nelson

9 (“Nelson Decl.”) ¶¶ 22 (HSAW Creams), 26 (All RWR Products).) A second (or  
 10 third) purchase is very unlikely to have been the result of misleading advertising,  
 11 and shows they received the benefit of their bargain the first time. Such consumers  
 12 suffered no injury, have no damages, and Plaintiff does not—and cannot—tailor her  
 13 proposed class to exclude them. Certification must be denied because (among other  
 14 reasons) the proposed class encompasses many unharmed members.

15 Plaintiff also offers no feasible way to calculate damages on a class-wide  
 16 basis, and reliance and materiality cannot be presumed here. Plaintiff’s proposed  
 17 class is not ascertainable, and she offers no plan for managing this case. Indeed,  
 18 Plaintiff’s own extensive history of skin problems and treatments, including severe  
 19 facial rashes from toxic mold and—at age 32—five Botox injections in the past two  
 20 years, shows the problems a trial of each individual’s claims will present.

21 **II. BACKGROUND FACTS<sup>1</sup>**

22 **A. The Six Products at Issue**

23 Two of the products—which Plaintiff bought in “early 2011”—are from  
 24 Neutrogena’s popular Healthy Skin Anti-Wrinkle line, and have been on the market  
 25 since the late 1990s.<sup>2</sup> Healthy Skin Anti-Wrinkle Cream SPF 15 (“HSAW SPF

27 <sup>1</sup> Although some of the facts and evidence set out below impact the merits of  
 28 Plaintiff’s claims, they also bear directly on issues critical to class certification.

<sup>2</sup> Declaration of Renee Yang (“Yang Decl.”) ¶ 2.

1 15"'), is a moisturizing cream that, as its name suggests, includes sunscreen, and  
 2 Healthy Skin Anti-Wrinkle Cream Night ("HSAW Night") is for use at night. The  
 3 other products, which Plaintiff purchased in "late 2011," are from the Rapid  
 4 Wrinkle Repair line, launched in February 2011.<sup>3</sup> They include a day cream (with  
 5 sunscreen) ("RWR Day"), and night ("RWR Night") and eye creams ("RWR  
 6 Eye").<sup>4</sup> They also include a serum ("RWR Serum") which Plaintiff never bought.<sup>5</sup>

7 **B. Retinol**

8 All of these products contain retinol, a form of vitamin A. When applied to  
 9 the skin, retinol is absorbed by skin cells and converted to retinoic acid, which  
 10 stimulates production of collagen, elastin, hyaluronic acid, and new skin cells, and  
 11 speeds up skin cell turnover.<sup>6</sup> Decades of research have proven retinol to be  
 12 effective, and today it is used in many cosmetic products to reduce the appearance  
 13 of fine lines, age spots, and other signs of aging in the skin.<sup>7</sup>

14 [REDACTED]

15 Redacted

16 [REDACTED] *Id.*

17 Other ingredients in the products, including glycerin, can also improve users' skin.<sup>8</sup>

18 Redacted

19 [REDACTED] 9

20 **C. Independently Conducted Scientific Studies Confirm That the**  
 21 **Products Deliver Benefits for Many Consumers**

22 A mountain of scientific studies from the past four decades shows that retinol

24 <sup>3</sup> Chow Decl. ¶ 5; Yang Decl. ¶ 3.

25 <sup>4</sup> Declaration of Sidney Hornby ("Hornby Decl.") ¶ 2.

26 <sup>5</sup> Compare First Amended Complaint ("FAC"), D.E. 13, ¶ 76 with Declaration of  
 27 Matthew D. Powers ("Powers Decl."), Ex. 1 [Pl.'s Dep. Excerpts] at 131:9-14.

<sup>6</sup> Powers Decl., Ex. 2 [Expert Report of Leslie Baumann M.D.] at 5-9.

<sup>7</sup> *Id.*, Ex. 2 [Baumann Report] at p. 10.

<sup>8</sup> Powers Decl., Ex. 2 [Baumann Report] at 11-14.

<sup>9</sup> Hornby Decl. ¶ 5.

1 can visibly reduce wrinkles and other signs of aging.<sup>10</sup> In addition to that publicly  
2 available data, Neutrogena also commissioned clinical studies to evaluate the  
3 products at issue here. Those studies were conducted by Dr. James Leyden, a  
4 medical doctor and professor of Dermatology at the University of Pennsylvania.<sup>11</sup>

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Redacted

<sup>10</sup> Powers Decl., Ex. 2 [Baumann Report] at 4-13.

<sup>11</sup> Hornby Decl. ¶ 7-8, 16.

<sup>12</sup> *Id.* ¶ 17, Ex. 1 at NTG00001477-78.

<sup>13</sup> Leyden Decl. ¶¶ 15-16 and Ex. 1 [Study 3899]; Hornby Decl. ¶ 18; Hornby Decl., Ex. 1 [Summary] at p. 1.

<sup>14</sup> Leyden Decl. ¶ 20 and Ex. 2 [Study 4239]; Hornby Decl. ¶¶ 16, 19.

1  
2  
3  
4  
Redacted5           **D. Different Consumers Have Different Reactions to Retinol**6           While the vast majority of retinol users will see improvement in their skin  
7           over time, the extent, nature, and timing of those improvements can vary.<sup>16</sup> How an  
8           individual responds will be affected by many factors, including genetics (skin type),  
9           lifestyle (tobacco use), and environment (sun exposure; air pollution; hot/humid vs.  
10           cool/dry).<sup>17</sup>11  
12           Redacted

13           19

14           **E. Different Messages Were Used to Promote the Products**15           Despite Plaintiff's assertion that the marketing of these products was  
16           "uniform," the particular statements seen by each consumer vary considerably.  
17           Most of the claims Plaintiff challenges are located only on the back of the products'  
18           packages. Yet according to Plaintiff's own allegations, the "vast majority of  
19           consumers" did not read the back of the package before buying the products. (FAC  
20           ¶ 90.) Moreover, Neutrogena has used different media and ads to promote the  
21           RWR products at different times. Neutrogena ran four print ads, each with a  
22           different message. The initial ads stated that "100% of women" in a study saw  
23           "noticeable results." (Yang Decl., Ex. 1.) Later ads say the products are "clinically24  
25           <sup>15</sup> Leyden Decl. Ex. 5; Hornby Decl. ¶ 15. These are only some of the results that  
26           have been shown by the many studies of these products.  
27           <sup>16</sup> Powers Decl., Ex. 2 [Baumann Report] at 11-18.  
28           <sup>17</sup> *Id.*, Ex. 2 [Baumann Report] at 14-18.  
29           <sup>18</sup> Leyden Decl. Ex. 4 [Study 6949] at Table at p. 8  
30           Redacted31           <sup>19</sup> *Id.*, Ex. 4 [Study 6949] at Table at p. 10.

1 proven" to "smooth" or "visibly reduce" wrinkles in one week. (*Id.*, Exs. 2-4.) The  
 2 statements in the television ads also varied in content and over time. (*Compare*,  
 3 *e.g.*, *id.* Ex. 5 (2011 ad) ("fastest retinol formula available") with Ex. 13 (2012 ad)  
 4 ("visibly reduce" wrinkles)). Neutrogena also advertised the products on "banner  
 5 ads" on Internet websites, none of which include any statements Plaintiff  
 6 challenges. (*Id.*, Ex. 10.) Instead, they note only that the products have the "fastest  
 7 retinol formula available." (*Id.*) And Neutrogena's website provides even more  
 8 information about the RWR products. (*Id.*, Ex. 11.)

9 **Redacted**

10 Like many companies, Neutrogena tracks data about its products and  
 11 customers, including the number of consumers who buy products on more than one  
 12 occasion. That data is very important to Neutrogena because it indicates consumer  
 13 satisfaction with its products. The repeat purchaser data for these products is  
 14 striking, and shows that

15

16

17

18

19 **Redacted**

20

21

22

23

24

25 <sup>20</sup> Nelson Decl. ¶ 22 (HSAW), 26 (RWR).

*Id.* ¶¶ 14-15.

26 **Redacted**

27 *Id.* at ¶ 26.

28 <sup>22</sup> *Id.* ¶¶ 18 (RWR Day), 16 (RWR Night), 24 (RWR Creams). Data regarding  
 RWR Eye specifically was not available. *Id.* ¶ 14.

Redacted

## **G. The National Advertising Division's Report**

4 In her Motion, Plaintiff cites a report from the National Advertising Division  
5 of the Council of Better Business Bureaus (“NAD”)<sup>23</sup> and claims that the “NAD  
6 concluded that none of the testing proffered by Neutrogena supported Neutrogena’s  
7 claims . . . .” (Mot. at 9.) That is false. In the actual report, which Plaintiff did not  
8 submit, the NAD concluded Neutrogena’s studies showed “significant win[s]” for  
9 its products against popular competitors: “a head-to-head comparison versus Estée  
10 Lauder Perfectionist Wrinkle Lifting Serum . . . showed a ***very significant win*** for  
11 the Neutrogena product” and “Neutrogena Rapid Wrinkle Repair, when compared  
12 across studies, ***has a significantly faster onset of action*** than either product.”<sup>24</sup> The  
13 NAD’s criticism was only over ***one*** RWR print ad which, in the NAD’s view,  
14 suggested that wrinkles would disappear completely after one week (a claim  
15 Neutrogena has never made).<sup>25</sup> Redacted

Redacted

Redacted

<sup>26</sup> and the class includes members who only . Notably, the NAD *agreed* that the RWR   
ula available.<sup>27</sup>

### III. PLAINTIFF HAS FAILED TO MEET HER EVIDENTIARY BURDEN TO SHOW THAT RULE 23'S REQUIREMENTS ARE SATISFIED

Plaintiff's motion must be rejected because she has failed to offer evidence demonstrating that the requirements of Rule 23 are satisfied. At a minimum, Plaintiff was required to identify the common evidence she will use at trial to prove her supposed common issues. *See, e.g., Gen. Tel. Co. of Sw. v. Falcon*, 457 U.S.

<sup>23</sup> The NAD is an industry group that seeks to bolster confidence in advertising by working with companies to ensure they have support for their advertisements.

<sup>24</sup> Hornby Decl., Ex. 6 [NAD Report] at 2 (emphasis added).

<sup>25</sup> *Id.*, Ex. 6 [NAD Report] at 6.

<sup>26</sup> Hornby Decl. ¶ 26.

<sup>27</sup> Hornby Decl., Ex. 6 [NAD Report] at 6 (emphasis added).

1 147, 158-59, 102 S. Ct. 2364, 72 L. Ed. 2d 740 (1982) (“Without any specific  
 2 presentation identifying the questions of law or fact that were common ... it was  
 3 error ... to presume that respondent’s claim was typical of other claims. . . .”);  
 4 *Gartin v. S & M NuTec LLC*, 245 F.R.D. 429, 435 (C.D. Cal. 2007) (“plaintiff must  
 5 provide evidence ... that Rule 23(b)(3) has been satisfied; mere promises that issues  
 6 relating to predominance or superiority can be overcome are inadequate.”).  
 7 Plaintiff did not do so. Instead, she argues that “in analyzing whether plaintiff has  
 8 met her burden to show that the [] requirements [of Rule 23] are satisfied, the  
 9 allegations of the plaintiff’s complaint are taken as true” and “[g]enerally, courts do  
 10 not make a preliminary inquiry regarding the merits.” (Mot. at 21.) That is not the  
 11 law. Plaintiff must submit *evidence* showing that Rule 23 is satisfied. *Dukes*, 131  
 12 S. Ct. at 2551.<sup>28</sup> Indeed, as many courts have held, Plaintiff must prove Rule 23’s  
 13 requirements have been met by a preponderance of the evidence.<sup>29</sup>

14 Although Plaintiff identifies seven purportedly common issues (e.g., “Does  
 15 Defendant possess . . . evidence supporting its advertising claims”; “Is Defendant’s  
 16 advertising untrue or misleading within the meaning of the UCL and FAL?”), those  
 17 issues all boil down to two basic questions: (1) does each product offer *any* users  
 18 *any* of the advertised benefits, and (2) are the class members entitled to any  
 19 monetary relief “and, if so, how much are they entitled to?” (Mot. at 24.) To be  
 20 “common,” the “claims must depend upon a common contention . . . capable of

---

21  
 22 <sup>28</sup> See also *Zinser v. Accufix Research Inst., Inc.*, 253 F.3d 1180, 1186 (9th Cir. 2001); *Doninger v. Pac. Nw. Bell, Inc.*, 564 F.2d 1304, 1309 (9th Cir. 1977) (certification denied where plaintiffs supplied “meager support” for certification and the only affidavits were from counsel); *Szabo v. Bridgeport Machs., Inc.*, 249 F.3d 672, 675 (7th Cir. 2001) (“The proposition that a district judge must accept all of the complaint’s allegations when deciding whether to certify a class cannot be found in Rule 23 . . . .”).

23  
 24  
 25 <sup>29</sup> See *In re Hydrogen Peroxide Antitrust Litig.*, 552 F.3d 305, 320 (3d Cir. 2008) (“Rule 23 findings must be made by a preponderance of the evidence”); *Teamsters Local 445 v. Bombardier, Inc.*, 546 F.3d 196, 202 (2d Cir. 2008) (same); *Cholakyan v. Mercedes-Benz USA, LLC*, 281 F.R.D. 534, 551 (C.D. Cal. 2012) (noting that no “Ninth Circuit authority . . . directs use of a preponderance standard” but applying that standard “[b]ecause that is the general standard of proof used in civil cases”).

1 classwide resolution—which means that determination of its truth or falsity will  
 2 resolve an issue that is central to the validity of each one of the claims in one  
 3 stroke.” *Dukes*, 131 S. Ct. at 2551. Although for purposes of Rule 23(a)(2) a  
 4 single common question will do, “[w]hat matters . . . is not the raising of common  
 5 ‘questions’—even in droves—but, rather the capacity of a classwide proceeding to  
 6 generate common answers apt to drive the resolution of the litigation.” *Id.*

7 Here, the evidence is overwhelming that these products can and do provide a  
 8 variety of benefits. (Powers Decl., Ex. 2 [Baumann Report] at 11-14.) Many  
 9 individualized factors can affect the degree to which consumers experience those  
 10 benefits, including environment (humidity and sun exposure), use, and skin type.

11 (*Id.* at 14-18.)

**Redacted**

12 **Redacted** proves that many derive substantial benefits from them. (Nelson  
 13 Decl. ¶¶ 22, 26.) Yet other than *allege* the products are “worthless,” Plaintiff does  
 14 nothing to show how she will prove that any of the statements she challenges are  
 15 false or which members of the class have been injured, much less how she will do  
 16 so with common evidence. *See Nat'l Council Against Health Fraud, Inc. v. King*  
 17 *Bio Pharm., Inc.*, 107 Cal. App. 4th 1336, 1342 (2003) (plaintiff has the burden to  
 18 prove advertising claims are misleading).

19 Plaintiff cannot simply claim she will prove a lack of scientific  
 20 substantiation. *See Stanley v. Bayer Healthcare LLC*, 2012 WL 1132920 (S.D. Cal.  
 21 Apr. 3, 2012). “Private individuals may not bring an action demanding  
 22 substantiation for advertising claims” under the UCL or CLRA. *Id.* at \*3. Because  
 23 an “alleged lack of substantiation does not render claims false and misleading under  
 24 the UCL or CLRA,” Plaintiff must prove, with evidence, that the claims violate  
 25 those statutes—asserting that claims are “actually false because they lack[ed]  
 26 proper scientific substantiation” is *not* enough. *Id.* at \*4-\*5. Plaintiff has submitted  
 27 literally no proof on that issue or shown how she will prove such claims at trial.

28 In fact, Plaintiff’s proposed trial would be a “heads they win, tails you lose”

1 proceeding for Neutrogena. Defeating Plaintiff's claim that the products are  
 2 "worthless" (e.g., by showing that the products have benefits for some (or many)  
 3 users) would not resolve the class' claims—proving that the products have benefits  
 4 for many does not necessarily mean that *no* individual has any claim. And Plaintiff  
 5 cannot fix that problem by limiting the class to those who are entitled to relief  
 6 because they did not receive the expected benefits—doing so would create an  
 7 impermissible "failsafe"<sup>30</sup> class. *See, e.g., Randleman v. Fidelity Nat. Title Ins.*  
 8 *Co.*, 646 F.3d 347, 352 (6th Cir. 2011) (class that only included those "entitled to  
 9 relief," was a failsafe class because "[e]ither the class members win or, by virtue of  
 10 losing, they are not in the class"); *Boucher v. First Am. Title Ins. Co.*, 2012 WL  
 11 3023316, at \*4 (W.D. Wash. July 24, 2012) ("Fail-safe classes are impermissible  
 12 because they make it impossible for a defendant to prevail against the class.").

13 Plaintiff's boilerplate assertions of "common issues" are unsupported by the  
 14 evidence, and her overly simplistic proposed class trial on whether "Defendant's  
 15 advertising [is] untrue" will do little (if anything) to "generate common answers apt  
 16 to drive the resolution of the litigation." *Dukes*, 131 S. Ct. at 2551 (italics  
 17 omitted). Plaintiff's motion should be denied on that basis alone.

18 **IV. STATE LAW VARIATIONS PRECLUDE CERTIFICATION OF A  
 19 NATIONWIDE UNDER RULE 23(b)(2) OR (b)(3)**

20 Plaintiff's proposed nationwide class will require the Court to apply the laws  
 21 of all 50 states, dwarfing any claimed common issues.<sup>31</sup> The Ninth Circuit's recent

---

22  
 23 <sup>30</sup> "[A] fail-safe class . . . is simply a way of labeling the obvious problems that  
 24 exist when the class . . . is defined in a way that precludes membership unless . . .  
 25 liability . . . is established. When the class is so defined, once it is determined that a  
 26 person, who is a possible class member, cannot prevail against the defendant, that  
 27 member drops out of the class. That is palpably unfair to the defendant, and is also  
 28 unmanageable—for example, to whom should the class notice be sent?" *Kamar v.*  
*RadioShack Corp.*, 375 Fed. Appx. 734, 735-36 (9th Cir. 2010).

<sup>31</sup> *See Zinser*, 253 F.3d at 1189 ("differences in state law will compound the  
 27 disparities among class members from the different states."); *In re*  
*Bridgestone/Firestone Tire Litig.*, 288 F.3d 1012, 1015 (7th Cir. 2002) ("No class  
 28 action is proper unless all litigants are governed by the same legal rules.").

1 decision in *Mazza v. American Honda* is directly on point, and the state-law-  
 2 variations analysis that Plaintiff failed to undertake confirms that a nationwide class  
 3 is unworkable here. *Mazza*, 666 F.3d at 590-94; *Zinser*, 253 F.3d at 1186-90; *In re*  
 4 *Bridgestone/Firestone*, 288 F.3d at 1018 (“[s]tate consumer-protection laws vary  
 5 considerably, and courts must respect these differences rather than apply one state’s  
 6 law to sales in other states with different rules.”).

7 **A. A Class Cannot Be Certified Where the Claims of Putative Class  
 8 Members Must Be Assessed Under the Laws of Multiple States**

9 A class may not be certified where, as here, the relevant claims and defenses  
 10 will be controlled by many states’ laws. Plaintiff’s claims arise exclusively under  
 11 state law and are brought on behalf of claimants in all 50 states and the District of  
 12 Columbia—*i.e.*, in every jurisdiction where the products are sold. (Yang Decl. at ¶  
 13 19.) Because “[n]o class action is proper unless all litigants are governed by the  
 14 same legal rules,” *In re Bridgestone/Firestone*, 288 F.3d at 1015, courts have  
 15 repeatedly refused to certify nationwide classes where the relevant state laws varied  
 16 from state to state. *E.g.*, *Mazza*, 666 F.3d at 594; *Zinser*, 253 F.3d at 1186-90;  
 17 *Bonlender v. Am. Honda Motor Co.*, 286 F. Appx. 414, 414-15 (9th Cir. 2008).

18 While an analysis of state-law variations is usually performed in the context  
 19 of “predominance” under Rule 23(b)(3), whether there is a commonly applicable  
 20 legal regime also impacts each subsection of Rule 23(b). The Advisory Committee  
 21 Notes for the 1966 Amendments to Rule 23(b)(2), for example, observe that  
 22 certification may be had when “settling the legality of the behavior with respect to  
 23 the class as a whole is appropriate.” Rule 23(b)(2) Adv. Com. Notes (1966  
 24 Amendments). When a court cannot determine the legality of the defendant’s  
 25 conduct as to all class members without considering the laws of each jurisdiction, a  
 26 (b)(2) class cannot be certified. In fact, “numerous courts have concluded that state  
 27 law variations create overwhelming obstacles to certification under Rule 23(b)(2).”  
 28 *Agostino v. Quest Diagnostics Inc.*, 256 F.R.D. 437, 466-70 (D.N.J. 2009) (denying

<sup>32</sup>certification of Rule 23(b)(2) class based on state law variations).

**B. California's "Governmental Interest" Test Requires the Application of the Law of Each Consumer's State of Purchase**

This court must look to the forum state's choice of law rules to determine the controlling substantive law, and under California's choice of law rules, "California law may only be used on a classwide basis if 'the interests of other states are not found to outweigh California's interest in having its law applied,'" as determined by a three-step "governmental interest" test. *Mazza*, 666 F.3d at 589-90 (quoting *Wash. Mut. Bank v. Superior Court*, 24 Cal. 4th 906, 921 (2001)). That test first considers whether the "law in each potentially concerned state . . . materially differs from the law of California." *Wash. Mut.*, 24 Cal. 4th at 919. If it does, the court must determine whether each other state has an interest "in having its own law applied," and, then, which state's interests would be "'more impaired' if its law were not applied." *Id.* at 920; *Mazza*, 666 F. 3d at 590. Here, just as in *Mazza*, Plaintiff's claims cannot be certified because "each class member's consumer protection claim should be governed by the consumer protection laws of the jurisdiction in which the transaction took place." *Id.* at 594. *See also Keegan v. Am. Honda Motor Co.*, 2012 WL 2250040, at \*37-40 (C.D. Cal. June 12, 2012) (same conclusion for express warranty).

## 1. Different States' Laws Vary in Material Ways

***Consumer Protection Statutes.*** As many courts have held, state consumer protection laws vary in material ways, including on statutes of limitations, scienter,

<sup>32</sup> See also *Sanders v. Johnson & Johnson, Inc.*, 2006 U.S. Dist. LEXIS 35881, at \*10-20 (D.N.J. May 31, 2006) (“These individualized factual issues, coupled with the individual application of different state laws . . . would swamp any common issues of fact between the class members.”); *Block v. Abbott Labs.*, 2002 WL 485364, at \*8 (N.D. Ill. Mar. 29, 2002) (“[s]ignificant variations in applicable state laws, combined with overwhelming factual variations in each class member’s case, preclude any finding that the interests of the class members are cohesive and homogenous.”); *Clay v. Am. Tobacco Co.*, 188 F.R.D. 483, 495 (S.D. Ill. 1999) (“[e]ven if the necessary prerequisites had been met, the claim is totally unmanageable as a class action because of the variations in state law . . . ”).

1 reliance and causation, the availability of class actions, damages, statutory  
 2 penalties, and punitive damages. *See, e.g., Gianino v. Alacer Corp.*, 2012 U.S. Dist.  
 3 LEXIS 32261, at \*6-7, \*11-12 (C.D. Cal. Feb. 27, 2012); *Mazza*, 666 F.3d at 590-  
 4 91; *In re Hitachi Television Optical Block Cases*, 2011 WL 9403, at \*6 (S.D. Cal.  
 5 Jan. 3, 2011); *In re St. Jude Med., Inc.*, 425 F.3d 1116, 1120 (8th Cir. 2005);  
 6 *Bridgestone/Firestone*, 288 F.3d at 1018.<sup>33</sup>

7 The statutes of limitations here differ substantially from those in other states,  
 8 and claims that might be timely here would be barred elsewhere.<sup>34</sup> In addition,  
 9 California allows class actions, while several states do not, *see La. Rev. Stat. Ann.*  
 10 § 51:1409(A); *Miss. Code Ann.* § 75-24-15(4), and although “[the UCL and  
 11 CLRA] have no scienter requirement . . . many other states’ consumer protection  
 12 statutes do require scienter.”<sup>35</sup> Again, those differences matter in this case, since  
 13 Plaintiffs will be unable to show any intent to mislead on Neutrogena’s part.  
 14 Standards for reliance and causation—which can “spell the difference between the  
 15 success and failure of the claim”—also vary. *Keegan*, 2012 WL 2250040, at \*33.  
 16 In many states, reliance may be required,<sup>36</sup> or, like California, the named plaintiff  
 17 must prove reliance. *In re Tobacco II*, 46 Cal. 4th 298, 298 (2009). But in others,  
 18

19

---

 20 <sup>33</sup> A complete analysis of the variations in state consumer protection and express  
 21 warranty laws is set out in Appendices 1 and 2.

22 <sup>34</sup> Cf. *Cal. Civ. Code* § 1783 (CLRA—three years from date of improper practice);  
 23 *Cal. Bus. & Prof. Code* § 17208 (UCL—four years); *Cal. Bus. & Prof. Code*  
 24 § 17500; *Cal. Civ. Proc. Code* § 338(d) (FAL—three years from discovery of facts  
 25 constituting fraud) *with Or. Rev. Stat.* § 6469-638(6) (one year from discovery of  
 26 deceptive practice); *Va. Code Ann.* § 59.1-204.1(A) (two years); *Ariz. Rev. Stat.*  
 27 *Ann.* § 12-541(5) (one year from discovery); *and see R.I. Gen. Laws* § 9-1-13 (ten  
 28 years); *see also Keegan*, 2012 WL 2250040, at \*335-36 (material differences in  
 state consumer protection statutes of limitation).

<sup>35</sup> *Mazza*, 666 F.3d at 591. *See, e.g., Colo. Rev. Stat.* § 6-1-105(1)(e), (g), (u)  
 (knowingly); *N.J. Stat. Ann.* § 56:8-2 (intent for omissions); *Debbs v. Chrysler*  
*Corp.*, 810 A.2d 137, 155 (Pa. Super. 2002) (knowledge or reckless disregard).

<sup>36</sup> *E.g., Kuehn v. Stanley*, 91 P.3d 346, 351 (Ariz. App. 2004); *Ga. Code Ann.* § 10-  
 1-399; *Baranco, Inc. v. Bardshaw*, 456 S.E.2d 592, 594 (Ga. App. 1995); *Ind. Code*  
*Ann.* § 24-5-05-4(a); *Valente v. Sofamor*, S.N.C., 48 F. Supp. 2d 862, 874 (E.D.  
 Wis. 1999).

1 it is not,<sup>37</sup> and, as discussed below, whether each class member relied on any  
 2 allegedly false statement will be a critical issue in this case. Remedies also differ—  
 3 while the UCL allows only restitution, consumers in other states can recover actual,  
 4 punitive, and sometimes statutory damages, depending on the circumstances.<sup>38</sup>

5 **Express Warranty Claims.** States' express warranty laws also vary. See  
 6 *Keegan*, 2012 WL 2250040, at \*37-41 (material differences in New York,  
 7 California, and North Carolina warranty laws); *Rikos v. Procter & Gamble Co.*,  
 8 2012 WL 641946 (S.D. Ohio Feb. 28, 2012) (rejecting nationwide class under  
 9 California choice of law rules because of differences in warranty laws).<sup>39</sup> In  
 10 California, reliance may be presumed, but any presumption can be overcome. *E.g.*,  
 11 Cal. Com. Code § 2313; *Weinstat v. Dentsply Int'l, Inc.*, 180 Cal. App. 4th 1213,  
 12 1229 (2010); Cal. Com. Code § 2313, U.C.C. cmt. 3. In Virginia, reliance may not  
 13 be required. *Daughtrey v. Ashe*, 413 S.E.2d 336, 338-39 (Va. 1992). In  
 14 Washington, the plaintiff must have been aware of the representations. *Baughn v.*  
 15 *Honda Motor Co.*, 727 P.2d 655, 669 (Wash. 1986). New Jersey shifts the burden  
 16 to defendant to show the plaintiff *disbelieved* the ad. *Cipollone v. Liggett Grp.,*  
 17 *Inc.*, 893 F.2d 541, 569 n.34 (3d Cir. 1990), *aff'd in part & rev'd in part*, 505 U.S.  
 18

19 <sup>37</sup> *E.g., Davis v. Powertel, Inc.*, 776 So. 2d 971, 973-74 (Fla. App. 2000); *Sebago, Inc. v. Beazer E., Inc.*, 18 F. Supp. 2d 70, 103 (D. Mass. 1998) (Mass. law);  
 20 *Stutman v. Chem. Bank*, 731 N.E.2d 608, 611-12 (N.Y. 2000); *Stephenson v. Capano Dev., Inc.*, 462 A.2d 1069, 1074 (Del. 1983); *Izzarelli v. R.J. Reynolds Tobacco Co.*, 117 F. Supp. 2d 167, 176 (D. Conn. 2000).

21 <sup>38</sup> See, e.g., 815 Ill. Comp. Stat. 505/2S & 10a. (statutory and compensatory damages); S.D. Codified Laws § 37-24-31 (actual/compensatory only); Miss. Code Ann. § 78-24-15(1) (compensatory only); Colo. Rev. Stat. Ann. §§ 6-1-113(2)(a) (only actual damages in class action); *Ford Motor Co. v. Sperau*, 708 So. 2d 111 (Ala. 1997) (punitive damages); Alaska Stat. §§ 45.50.531(a)(i), 45.50.535 (punitive damages, but 50% go to the state); *Howell v. Midway Holdings, Inc.* 362 F. Supp. 2d 1158, 1165 (D. Ariz. 2005) (punitive damages for wanton, reckless, "spite" or "ill will."); Ark. Code Ann. § 4-88-204 (punitive damages for disabled and elderly); Mich. Comp. Laws Ann. § 445-905(1) (punitive damages for persistent and knowing, but cannot exceed \$25,000); N.M. Stat. Ann. § 57-12-10(E) (limited statutory damages for named plaintiff without actual damages); Ohio Rev. Code Ann. § 1345-09(A)(B) (allowed in individual action).

22 <sup>39</sup> A complete analysis of state express warranty laws is set out in Appendix 2.

1 504 (1992). North Carolina may require reliance, but with lesser proof if  
 2 affirmations of fact were made during negotiations. *Harbor Point Homeowners'*  
 3 Ass'n, Inc. ex rel. Bd. of Dirs. v. DJF Enters., Inc., 697 S.E.2d 439 (N.C. App.  
 4 2010); N.C. Gen. Stat. § 25-2-313 cmt. 3. And New York can require reliance.  
 5 *Horowitz v. Stryker Corp.*, 613 F. Supp. 2d 271, 286 (E.D.N.Y. 2009). Thus,  
 6 applying California law could, for example, allow residents of New York or  
 7 Washington to bring claims that might be barred in their home states.

8 Pre-suit notice requirements differ as well. E.g., *Keegan*, 2012 WL 2250040,  
 9 at \*39 (pre-suit notice materially different in New York, California and North  
 10 Carolina). In California, notice is not required if the consumer did not deal directly  
 11 with the manufacturer. *Stearns v. Select Comfort Retail Corp.*, 763 F. Supp. 2d  
 12 1128, 1142-43 (N.D. Cal. 2010); *Sanders v. Apple, Inc.*, 672 F. Supp. 2d 978, 989  
 13 (N.D. Cal. 2009). South Carolina requires notice to the immediate seller, *Seaside*  
 14 *Resorts, Inc. v. Club Car, Inc.*, 416 S.E.2d 655, 663 (S.C. App. 1992), and New  
 15 York does not require notice for consumer transactions. *Fischer v. Mead Johnson*  
 16 *Labs*, 341 N.Y.S.2d 257, 258 (N.Y.A.D. 1973). But in North Carolina, notice may  
 17 be required for manufacturers and sellers—the question appears unsettled. See  
 18 *Halprin v. Ford Motor Co.*, 420 S.E.2d 686, 688-89 (N.C. App. 1992). The timing  
 19 of notice also varies—in Massachusetts a three-and-a-half-month delay barred suit,  
 20 *P & F Constr. Corp. v. Friend Lumber Corp.*, 575 N.E.2d 61, 64 (Mass. App.  
 21 1991), but in Florida, six months was held to not be untimely, *Lafayette Stabilizer*  
 22 *Repair, Inc. v. Mach. Wholesalers Corp.*, 750 F.2d 1290, 1294 (5th Cir. 1985), and  
 23 in North Carolina, a delay of three years was held to be acceptable. *Maybank v.*  
 24 *S.S. Kresge Co.*, 273 S.E.2d 681, 685 (N.C. 1981). Since most of these products  
 25 were sold by third-party retailers, these variations could have a significant impact  
 26 on many class members' claims—particularly where notice to the seller is required.

27 Finally, privity rules also differ. California may not require privity when  
 28 consumers relied on product labels or ads, *Fieldstone Co. v. Briggs Plumbing*

1 *Prods., Inc.*, 54 Cal. App. 4th 357, 369 n.10 (1997), but without showing privity,  
2 for example, in Arizona, warranty claims for retail purchases could be barred.  
3 *Flory v. Silvercrest Indus. Inc.*, 633 P.2d 383, 387 (Ariz. 1981). Thus, a consumer  
4 in Arizona who bought the product at Walgreens could not recover without proving  
5 privity—an essential requirement in that state.

## 2. Each State Has a Strong Interest in Applying Its Own Laws

7 Since the conflicts of law at issue here are material, the court must  
8 “determine what interest, if any, each state has in having its own law applied to the  
9 case.” *Wash. Mut.*, 24 Cal. 4th at 920. Consumer protection laws reflect important  
10 policy judgments by each state about the conduct permitted within its borders, and  
11 “each state has a strong interest in applying its own consumer protection laws to  
12 [the] transactions [that take place within its borders]”—even if another state’s law  
13 might be more favorable to consumers. *Mazza*, 666 F.3d at 591-92. Instead,  
14 “[e]ach state has an interest in setting the appropriate level of liability for  
15 companies conducting business within its territory” and it is error to “discount[] or  
16 not recogniz[e] each state’s valid interest in shielding out-of-state businesses from  
17 what the state may consider to be excessive litigation.” *Id.* at 592.<sup>40</sup> In fact, “[t]he  
18 importance of federalism when applying choice of law principles to class action  
19 certification is reinforced by the Class Action Fairness Act,” a “key purpose” of  
20 which was to prevent courts from dictating the “substantive laws of other states.”<sup>41</sup>  
21 *Id.* at 593 (quoting S. Rep. No. 109-14, at 61 (2005)).

### 3. Other States' Interests Would Be Impaired

23 The last prong of the choice-of-law analysis requires the court to determine  
24 "which state's interest would be more impaired if its policy were subordinated to

<sup>40</sup> See also *Lewallen v. Medtronic USA, Inc.*, 2002 WL 31300899, at \*5 (N.D. Cal. Aug. 28, 2002); *Zinser*, 253 F.3d at 1187 (“every state has an interest in having its law applied to its resident claimants.”); *Spence v. Glock, Ges.m.b.H.*, 227 F.3d 308, 314 (5th Cir. 2000) (states have an interest in choosing the breadth of recovery under their laws); *Bridgestone/Firestone*, 288 F.3d at 1018.

1 the policy of the other state.” *Mazza*, 666 F.3d at 590; *Offshore Rental Co. v. Cont'l*  
 2 *Oil Co.*, 583 P.2d 721, 726 (Cal. 1978); *Wash. Mut.*, 24 Cal. 4th at 920. Courts do  
 3 not weigh the worthiness of the respective laws, “but rather . . . decide—in light of  
 4 the legal question at issue and the relevant state interests at stake—which  
 5 jurisdiction should be allocated the predominating lawmaking power under the  
 6 circumstances of the present case.” *McCann v. Foster Wheeler LLC*, 48 Cal. 4<sup>th</sup> 68,  
 7 97 (Cal. 2010). Here, almost all of the relevant conduct took place outside  
 8 California. Consumers viewed the ads, bought the products, and used them in their  
 9 home states. And although Neutrogena is headquartered in Los Angeles, the RWR  
 10 advertising was developed by a New York-based team at Roberts & Langer. Two  
 11 of the products (HSAW Night and RWR Serum) are manufactured in Europe, ■■■■■

12 **Redacted**

(Yang Decl. ¶ 18-19.)

13 California recognizes that with respect to regulating conduct, “the place of  
 14 the wrong has the predominant interest,” and the location of the wrong is the “state  
 15 where the last event necessary to make the actor liable occurred.” *See Mazza*, 666  
 16 F.3d at 593. *See also* Restatement (Second) of Conflict of Laws § 148 (key to  
 17 conflicts-of-law analysis is the location where plaintiff receives representation and  
 18 acts in reliance). Here, that state is each consumer’s state of residence, which has a  
 19 very strong interest in regulating conduct within its borders and applying its own  
 20 laws to its own residents’ purchases. *Mazza*, 666 F.3d at 594; *Gianino*, 2012 U.S.  
 21 Dist. LEXIS 32261, at \*15-16. California’s interest in applying its law to foreign  
 22 transactions, on the other hand, is attenuated—especially here, where “the place of  
 23 the wrong” is each consumer’s home state. *See Edgar v. MITE Corp.*, 457 U.S. 624  
 24 (1982); *Gianino*, 2012 U.S. Dist. LEXIS 32261, at \*14-15; *Mazza*, 666 F.3d at 594.

25 **4. District Court Decisions Following *Mazza***

26 After *Mazza*, many courts have refused to apply California law to nationwide  
 27 classes. *See Gianino*, 2012 U.S. Dist. LEXIS 32261 at \*6-7, 11 (rejecting  
 28 nationwide class because of “significant variations in the states’ consumer

protection” laws); *Horvath v. LG Elecs. Mobilecomm U.S.A., Inc.*, 2012 U.S. Dist. LEXIS 19215, at \*5-11, 25-29 (S.D. Cal. Feb. 13, 2012) (dismissing out-of-state plaintiffs because applicable laws differed). And the few courts that have approved such classes after *Mazza* are distinguishable. In *Bruno v. Eckhart Corp.*, 280 F.R.D. 540, 542-43 (C.D. Cal. 2012), for example, the court refused to decertify a class on the grounds that *Mazza* was not a material change in the law and the defendant failed to analyze the other states’ laws. *Id.* at 543-44. And in *Cambridge Lane, LLC v. J-M Manufacturing Co.*, 2012 U.S. Dist. LEXIS 43533, at \*17-19 (C.D. Cal. Mar. 15, 2012), the defendant did not make a “sufficient showing” of state law variations, but the court noted it would likely decertify upon such a showing. *Id.* at \*18-19. Neutrogena has provided a detailed analysis of the material variations in states’ consumer protection and breach of warranty laws, both above and in Appendices 1 and 2. Since almost every element of every claim reflects substantial differences on basic elements of claims and recovery, Plaintiff’s proposed nationwide classes must be rejected. *See Mazza*, 666 F.3d at 594.

## 16     **V. PLAINTIFF’S 23(b)(2) CLASS FAILS**

17     Rule 23(b)(2) is limited. It applies only if “the party opposing the class has  
 18     acted or refused to act on grounds generally applicable to the class, thereby making  
 19     appropriate final injunctive relief or corresponding declaratory relief with respect to  
 20     the class as a whole.” Fed. R. Civ. P. 23(b)(2). Plaintiff argues Rule 23(b)(2)  
 21     applies because an injunction is supposedly her “primary goal.” (Mot. at 27-28.)  
 22     But Rule 23(b)(2) does not apply simply because “a plaintiff class, at its option,  
 23     combines its monetary claims with a request—even a ‘predominating request’—for  
 24     an injunction.” *Dukes*, 131 S. Ct. at 2559. Instead, “Rule 23(b)(2) applies only  
 25     where a single injunction or declaratory judgment would provide relief to each  
 26     member of the class. . . . [I]t does not authorize class certification when each class  
 27     member would be entitled to an individualized award of monetary damages.” *Id.* at  
 28     2557. Seeking damages *at all* “cast[s] doubt on the propriety of certifying a class

1 under Rule 23(b)(2).” *Cholakyan*, 281 F.R.D. at 560. Damage claims can **only** be  
 2 certified under Rule 23(b)(2) if the monetary relief is “merely incidental” to the  
 3 claim for an injunction. *Zinser*, 253 F.3d at 1195.<sup>41</sup>

4 Plaintiff’s claims are a far cry from a typical Rule 23(b)(2) case—e.g.,  
 5 seeking class-wide injunctions to redress uniform group injuries: violations of civil  
 6 rights, the First Amendment, due process, or denial of government benefits.<sup>42</sup>  
 7 Unlike such cases, the claims here cannot be certified because (1) an injunction will  
 8 not benefit the entire class, and (2) the monetary relief is not incidental. First, an  
 9 injunction will **not** provide relief to “each member of the class.” *Dukes*, 131 S. Ct.  
 10 at 2557; *Zinser*, 253 F.3d at 1195. Plaintiff seeks an order enjoining “false and  
 11 misleading statements” and requiring corrective advertising “to prevent Neutrogena  
 12 from fraudulently inducing future consumers into spending money on the  
 13 Products.” (FAC ¶¶ 87, 89.) Such an injunction will do nothing for past purchasers  
 14 who have no intention of buying again.<sup>43</sup> They have nothing to gain from

15

---

16 <sup>41</sup> Due process requires that the protections of Rule 23(b)(3) (notice and an  
 17 opportunity to opt out) be provided in a class action in which monetary damages are  
 18 sought, even if the injunctive claim is predominant. *See Ellis v. Costco Wholesale*  
*Corp.*, 657 F.3d 970, 986-87 (9th Cir. 2011) (citing *Dukes*, 131 S. Ct. at 2557-58).  
 19 And, Rule 23(b)(2)’s assumption that the class is homogeneous and cohesive “can  
 20 be destroyed by showing individualized issues as to liability or remedy.” *Manual*  
*for Complex Litigation* at 261 (4th ed.); *see also Lewallen*, 2002 WL 31300899, at  
 \*3 (“Even though [Rule 23(b)(2)] does not contain a predominance and superiority  
 21 requirement ... cohesiveness is lacking where individual issues predominate.”).

22 <sup>42</sup> *See, e.g., Arnold v. United Artists Theatre Circuit, Inc.*, 158 F.R.D. 439, 451-52  
 23 (N.D. Cal. 1994) (disabled theatergoers sought compliance with the ADA);  
*Petersen v. Talisman Sugar Corp.*, 478 F.2d 73, 83 (5th Cir. 1973) (labor union and  
 24 religious employees sought declaratory judgment allowing public to communicate  
 25 with workers); *Riley v. Nev. Supreme Court*, 763 F. Supp. 446, 452-53 (D. Nev.  
 26 1991) (challenging death penalty procedures); *Baby Neal ex rel. Kanter v. Casey*,  
 27 43 F.3d 48, 58 (3d Cir. 1994) (systemic failure to provide child welfare services).

28 <sup>43</sup> *See, e.g., Cholakyan*, 281 F.R.D. at 559 (former vehicle owners would not benefit  
 29 from injunction); *Dukes*, 131 S. Ct. at 2560 (former employees would not benefit  
 30 from injunctive relief); *Lozano v. AT&T Wireless Servs., Inc.*, 504 F.3d 718, 729  
 31 (9th Cir. 2007) (denying 23(b)(2) certification on UCL and CLRA claims for  
 32 deceptive billing practices); *Gonzalez v. Proctor & Gamble Co.*, 247 F.R.D. 616,  
 626-27 (S.D. Cal. 2007) (denying 23(b)(2) certification on UCL, CLRA, and breach  
 33 of express warranty claims that hair products were falsely represented as effective  
 34 in strengthening hair).

1 injunctive relief and “cannot make an end-run around Rule 23(b)(3) by tacking on a  
 2 request for an injunction.” *Cholakyan*, 281 F.R.D. at 561; *see also Drimmer v.*  
 3 *WD-40 Co.*, 2007 WL 2456003 at \*5 (S.D. Cal. Aug. 24, 2007) (“[t]he class  
 4 members, by definition, already purchased the products” and “an injunction  
 5 prohibiting the allegedly false statements can only benefit *future* purchasers.”)  
 6 (italics original). Here, consumers can directly observe these products’ effects;  
 7 “corrective” advertising would do nothing for past purchasers—or for past users  
 8 who *do* plan to buy again, who already know exactly how well the products work  
 9 *for them*. The *only* individuals who might benefit are future purchasers who have  
 10 never used the products—i.e., who are *not* members of the putative class.

11 Second, the monetary relief Plaintiff seeks is hardly incidental. *See Zinser*,  
 12 253 F.3d at 1195. As discussed above, the benefits to the class of an injunction are  
 13 illusory at best. And the monetary relief sought is extensive: restitution, actual  
 14 damages, punitive damages, attorneys’ fees, and prejudgment interest. (FAC,  
 15 Prayer for Relief.) Even the equitable relief is aimed at avoiding *damages*. (FAC  
 16 ¶¶ 87, 89.) Where, as here, “[t]he equitable relief requested is to prevent further  
 17 actions by the Defendant[] that would create further similar monetary damages. . .  
 18 nationwide class certification under Fed. R. Civ. P. 23(b)(2) [is] inappropriate.”  
 19 *Util. Consumers’ Action Network v. Sprint*, 259 F.R.D. 484, 489 (S.D. Cal. 2009).

20 Plaintiff cannot superficially structure her case around a claim for injunctive  
 21 relief if, in reality, the relief sought would require individualized remedy  
 22 determinations. *Cholakyan*, 281 F.R.D. at 560; *Ellis*, 657 F.3d at 987. Here, at a  
 23 minimum, each class member’s supposed damages will depend on how much he or  
 24 she paid for each product, how many products he or she purchased, and whether he  
 25 or she bought the products in connection with a promotion or other discount  
 26 program. Whether they suffered an injury *at all* will also depend on: whether they  
 27 experienced any benefit from the products, which marketing statements they were  
 28 exposed to, and whether they bought the same or a similar product again.

1 Individualized facts will be necessary to determine injury and damages, and courts  
 2 have rejected Rule 23(b)(2) classes under similar circumstances.<sup>44</sup>

3 Finally, since no one can opt out of a 23(b)(2) class, certification will  
 4 eliminate class members' ability to decide for themselves whether they prefer to  
 5 seek damages in lieu of injunctive relief. If the Court certifies a class and a  
 6 judgment is entered on the injunctive relief claims, res judicata and collateral  
 7 estoppel will prevent class members from recovering damages. *See, e.g., Crawford*  
 8 *v. Honig*, 37 F.3d 485, 487 (9th Cir. 1994); *Zachery v. Texaco Exploration &*  
 9 *Prods.*, 185 F.R.D. 230, 243-245 (W.D. Tex. 1999) (plaintiffs "are asking the class  
 10 members being represented here to risk waiving their right to monetary damages  
 11 solely so that the action for [an injunction] can proceed as a class action."). The  
 12 Court should reject Plaintiff's attempt to shoehorn her damages claims into the  
 13 limited framework of Rule 23(b)(2).

14 **VI. PLAINTIFF'S 23(b)(3) CLASS FAILS BECAUSE COMMON ISSUES  
 15 DO NOT PREDOMINATE OVER INDIVIDUALIZED ISSUES.**

16 Even if Plaintiff had satisfied Rule 23(a)'s prerequisites—she has not—she  
 17 must also satisfy Rule 23(b)(3) by proving that (1) common questions of fact and  
 18 law predominate over any questions affecting only individual members, and (2) a  
 19 class action is superior to alternate means of resolving the dispute. Fed. R. Civ. P.  
 20 23(b)(3); *Dukes*, 131 S. Ct. at 2541; *Lanzarone v. Guardsmark Holdings, Inc.*, 2006

21 <sup>44</sup> *See Lozano*, 504 F.3d at 718 (rejecting Rule 23(b)(2) class in suit involving  
 22 billing practices for cellular phone services); *Bolin v. Sears, Roebuck & Co.*, 231  
 23 F.3d 970, 976 (5th Cir. 2000) (plaintiffs may not "attempt to shoehorn damages  
 24 actions into the Rule 23(b)(2) framework"); *Edwards v. First Am. Corp.*, 251  
 25 F.R.D. 449, 452-53 (C.D. Cal. 2007) (rejecting Rule 23(b)(2) class because  
 26 monetary damages were the "essential goal" of the litigation); *Campion v. Old*  
 27 *Republic Home Prot. Co.*, 272 F.R.D. 517, 539 (S.D. Cal. 2011) (rejecting 23(b)(2)  
 28 class under UCL and CLRA for fraudulently inducing purchase of home warranty  
 policies); *Gonzalez*, 247 F.R.D. at 626-27 (no 23(b)(2) certification on UCL,  
 CLRA, and breach of express warranty claims that Pantene Pro-V hair products  
 were falsely represented as effective in strengthening hair); *In re Paxil Litig.*, 218  
 F.R.D. 242, 247 (C.D. Cal. 2003) (no 23(b)(2) certification of UCL class of Paxil  
 users); *Cholakyan*, 281 F.R.D. 534 (denying 23(b)(2) certification of class of  
 California vehicle lessees on UCL and CLRA claims for unlawful warranties).

1 WL 4393465, at \*4 (C.D. Cal. Sept. 7, 2006).

2 The essential question is whether issues “subject to generalized proof . . .  
 3 predominate over those issues that are subject only to individualized proof.”  
 4 *Williams v. Oberon Media, Inc.*, 2010 WL 8453723, at \*7 (C.D. Cal. April 19,  
 5 2010). Common issues predominate only when they constitute such a significant  
 6 aspect of the action that “there is a clear justification for handling the dispute on a  
 7 representative rather than on an individual basis.” *Antoninetti v. Chipotle Mexican  
 8 Grill, Inc.*, 2012 WL 3762440, at \*5-6 (S.D. Cal. Aug. 28, 2012). But if “a class  
 9 action ‘will splinter into individual trials,’ common questions do not predominate  
 10 and litigation of the action in the class format is inappropriate.”<sup>33</sup> *Akkerman v.  
 11 Mecta Corp.*, 152 Cal. App. 4th 1094, 1102 (2007) (internal citations and  
 12 references omitted). See also *Slaven v. BP Am., Inc.*, 190 F.R.D. 649, 657 (C.D.  
 13 Cal. 2000). To determine which aspects of the case are common, the Court must  
 14 review each element of Plaintiff’s causes of action and the facts necessary to litigate  
 15 those elements. See *Falcon*, 457 U.S. at 160 (“[T]he class determination generally  
 16 involves considerations that are ‘enmeshed in the factual and legal issues  
 17 comprising the plaintiff’s cause of action.’” (internal citation omitted)).

18 Here, each proposed class claim—under the UCL, CLRA, and breach of  
 19 express warranty—requires Plaintiff to prove that she and every class member were  
 20 exposed to a deceptive claim about one of the products, that there is at least some  
 21 causal link between the statement and their alleged harm, and that they incurred  
 22 monetary harm because of their purchases. Whatever evidence Plaintiff might  
 23 present in support of her individual claim could not prove (at least not in  
 24 accordance with due process) the claims of every class member. Among other  
 25 things, many class members have not suffered *any* injury, and adjudicating these  
 26 claims would require the Court to conduct a highly individualized inquiry into, for  
 27 each class member, (1) which, if any, allegedly misleading statements each saw;  
 28 (2) whether each of them bought the products based on those statements;

1 (3) whether each of them bought the products based on their prior personal  
 2 experience with them; and (4) whether each of them received any of the expected  
 3 benefits. These questions are simply not subject to common proof.

4 **A. Each Cause of Action Requires Proof of Causation or Reliance**

5 To recover damages under the **CLRA**, Plaintiff must “show not only that a  
 6 defendant’s conduct was deceptive but that the deception caused [the plaintiff]  
 7 harm.” *In re Vioxx Class Cases*, 180 Cal. App. 4th 116, 129 (2009) (citing *Mass.  
 8 Mut. Life Ins. Co. v. Superior Court*, 97 Cal. App. 4th 1282, 1292 (2002)). In other  
 9 words, for her CLRA claim Plaintiff must “prove she relied on a material  
 10 misrepresentation.”<sup>45</sup> Likewise, for **breach of express warranty**, Plaintiff must  
 11 show an “affirmation of fact or promise” about the product that became part of the  
 12 basis of the bargain. Cal. Com. Code § 2313(1)(a). Express warranty claims  
 13 therefore require reasonable reliance. *Moncada v. Allstate Ins. Co.*, 471 F. Supp. 2d  
 14 987, 997 (N.D. Cal. 2006) (“[u]nder the law relating generally to express warranties  
 15 a plaintiff must show reliance on the defendant’s representation.”); *Williams v.  
 16 Beechnut Nutrition*, 185 Cal. App. 3d 135, 142 (1986) (“one must allege the exact  
 17 terms of the warranty, plaintiff’s reasonable reliance thereon, and a breach of that  
 18 warranty which proximately causes plaintiff injury.”).<sup>46</sup>

19 Plaintiff’s **UCL** claim for restitution also requires a causal connection  
 20 between the alleged misconduct and harm allegedly suffered by absent class  
 21 members—Plaintiff’s argument that the UCL “lack[s] . . . any requirement to prove  
 22 actual falsity, reliance or damages” misstates the law. (E.g., Mot. at 12.)  
 23 *Tobacco II* did not render causation **irrelevant** as to absent class members. In fact, a

24 <sup>45</sup> *Brownfield v. Bayer Corp.*, 2009 U.S. Dist. LEXIS 63057, at \*9 (E.D. Cal.  
 25 July 2, 2009). See also *Cattie v. Wal-Mart Stores, Inc.*, 504 F. Supp. 2d 939, 946  
 26 (S.D. Cal. 2007); *Suzuki v. Hitachi Global Storage Techs., Inc.*, 2007 U.S. Dist.  
 LEXIS 51605, at \*16 (N.D. Cal. July 16, 2007).

27 <sup>46</sup> While some courts have said that express warranty does not contain a separate  
 28 requirement labeled “reliance,” even those courts acknowledge the statutory  
 requirement that plaintiff allege that defendant made an “affirmation of fact” that is  
 part of the basis of the bargain. See *Weinstat*, 180 Cal. App. 4th at 1227.

1 number of courts after *Tobacco II* have denied certification in UCL cases where  
 2 causation and reliance could not be litigated on a classwide basis. *Tucker v. Pac.*  
 3 *Bell Mobile Servs.*, 208 Cal. App. 4th 201, 228 (2012) (“[e]ven if we assume that  
 4 there were a common misrepresentation . . . and that the representations were  
 5 material, Plaintiffs could not present UCL class claims for restitution [here.]”);  
 6 *Sevidal v. Target Corp.*, 189 Cal. App. 4th 905, 924 (2010) (“Even after the  
 7 *Tobacco II* decision, the UCL and FAL still require some connection between the  
 8 defendant’s alleged improper conduct and the unnamed class members who seek  
 9 restitutionary relief.”); *Cohen v. DIRECTV, Inc.*, 178 Cal. App. 4th 966, 981 (2009)  
 10 (no certification of UCL class because of individualized issues of reliance);  
 11 *Campion*, 272 F.R.D. 517, 535 (S.D. Cal. 2011) (*Tobacco II* is limited to UCL  
 12 standing, not certification requirements; denying certification of UCL and CLRA  
 13 claims because of individualized issues of class members’ reliance on allegedly  
 14 deceptive statements pertaining to home warranty plans).

#### 15                   B.     Whether Any Consumer Was Injured Is An Individualized Issue

16                   Here, many class members suffered no injury. This means that the *fact* of  
 17 harm or injury—an element of all of Plaintiff’s claims<sup>47</sup>—is an individualized issue  
 18 not subject to class-wide proof. While variations in damage calculations alone will  
 19 not typically defeat certification, determining whether a class member was harmed  
 20 *at all* can overwhelm issues common to a class. *E.g., Wilens*, 120 Cal. App. 4th at  
 21 756 (class “inappropriate” when individual issues “go beyond mere calculation” of  
 22 damages and “involve each class member’s *entitlement* to damages.”).

23                   Even if Plaintiff proves that *some* misrepresentations were made to all class  
 24 members, that does *not* mean that everyone is entitled to restitution or that such a

25  
 26                   <sup>47</sup> See Section V.A, *supra*. Each cause of action requires plaintiff to show that the  
 27 members of the class suffered injury because of Neutrogena’s alleged conduct.  
 28 *E.g., Wilens v. TD Waterhouse Grp., Inc.*, 120 Cal. App. 4th 746 (2003) (CLRA);  
*Tobacco II*, 46 Cal. 4th at 328 (UCL); *Sevidal*, 189 Cal. App. 4th at 925, 928 (UCL  
 and CLRA); *Sanders*, 672 F. Supp. 2d at 987.

1 claim should be certified—even under the UCL. In *Tucker v. Pacific Bell Mobile*  
 2 *Services*, for example, the plaintiff sued his cellphone provider, claiming that “each  
 3 and every rate plan offered for sale” by the defendants “contain[ed] a material  
 4 misrepresentation with respect to the actual number of airtime minutes” covered by  
 5 the plan. *Tucker*, 208 Cal. App. 4th at 218. Because many customers had no  
 6 restitution claim, the Court refused to certify a class: “Even if we assume that there  
 7 were a common misrepresentation as to the number of conversational minutes in  
 8 the Defendants’ advertised rate plans, and that the representations were material,  
 9 Plaintiffs could not present UCL class claims for restitution.” *Id.* at 228.<sup>48</sup>

10 Although “relief under the UCL and FAL ‘is available without individualized  
 11 proof of deception, reliance, and injury’” those statutes “still require that plaintiffs  
 12 suffer injury in fact.” *See In re Google AdWords Litig.*, 2012 WL 28068, at \*10  
 13 (N.D. Cal. Jan. 5, 2012). And no class can be certified where, as here, “the  
 14 question of [who] among the hundreds of thousands of proposed class members are  
 15 even entitled to restitution would require individual inquiries.” *Id.* at \*14. In  
 16 *Google*, plaintiffs alleged deceptive practices in connection with Google’s  
 17 AdWords program—which “allows advertisers to create online advertisements and  
 18 display them through various channels on the Internet.” *Id.* at \*1. The program  
 19 was allegedly deceptive because some ads were placed on error pages or  
 20 undeveloped websites. But since such ads still had benefits for some class  
 21 members, certification was improper because “there [was] no systematic way to  
 22 identify and exclude from Plaintiffs’ proposed class the many advertisers who have  
 23 no legal claim to restitution because they derived direct economic benefits from ads  
 24

25  
 26 <sup>48</sup> *See also Campion*, 272 F.R.D. at 536 (S.D. Cal. 2011) (“[t]he fact the alleged  
 27 misrepresentations were made in the home warranty plans and a copy of the plan  
 28 was received by every class member does not, as Plaintiff posits, end the inquiry as  
 to whether common reliance should be inferred.”). *Cohen*, 178 Cal. App. 4th at  
 979-82 (class members not exposed to uniform representations were in a “myriad of  
 different positions” and some were not motivated by misrepresentations).

1 placed on parked domains and error pages.” *Id.* at \*11.<sup>49</sup> The Southern District of  
 2 Illinois recently reached the same conclusion when it rejected a putative UCL class  
 3 action over the marketing of an oral contraceptive. *In re Yasmin & Yaz*  
 4 (*Drospirenone*) *Mktg., Sales Pract. & Prod. Liab. Litig.*, 2012 WL 865041, at \*12,  
 5 \*19 (“in assessing whether a class is overly broad for purposes of class  
 6 certification, [the court] considers whether the putative class includes members who  
 7 could not possibly have been injured by the defendant’s conduct.”).

8 Here, many class members suffered no injury. Under no plausible  
 9 interpretation of the facts can it be said that a decision to buy these products *again*  
 10 was due to deceptive marketing, and Plaintiff’s bare allegation that the products are  
 11 “worthless” is rebutted by the overwhelming evidence that these products can and  
 12 do provide benefits to many users. (See Powers Decl. Ex. 2 [Baumann Report] at  
 13 11-14; Leyden Decl. ¶¶ 5, 7, 15-16, 17, 20, 21, 24, 31-33, 36; Hornby Decl. ¶¶ 12,  
 14 15, 17, 19, 22.) And, as discussed below, the statements to which consumers were  
 15

---

16 <sup>49</sup> *Stearns v. Ticketmasters Corp.* (discussed in *In re Google*) has no application  
 17 here. 655 F.3d 1013 (9th Cir. 2011). **First**, the court in *Stearns* did not determine  
 18 that a class should be certified—it merely held that the trial court’s refusal to certify  
 19 a class (before the *Tobacco II* decision) was based on an inaccurate reading of the  
 20 UCL and remanded for reconsideration. **Second**, the court’s discussion of the UCL  
 21 focused on the standing (or lack thereof) of unnamed class members in light of  
 22 *Tobacco II*, and the court reiterated an earlier holding that “[i]n a class action,  
 23 standing is satisfied if at least one named plaintiff meets the requirements . . . .  
 24 Thus, we consider only whether at least one named plaintiff satisfies the standing  
 25 requirements.” *Id.* at 1021. Here, Neutrogena is not opposing Plaintiff’s Motion  
 26 because putative class members lack standing (although many do). Instead, as in  
 27 *Google*, certification must be denied here because (among other reasons) the  
 28 proposed class encompasses many unharmed members. See *Yasmin*, 2012 WL  
 865041, at \*19 (“In conducting its rule 23(b)(3) analysis [of a UCL claim], the  
 Court is concerned with the substantive elements necessary to maintain a claim and  
 establish entitlement to restitutionary relief; not the elements necessary for  
 establishing standing.”). **Third**, *Stearns*’ discussion of the CLRA is distinguishable  
 because, as the court explained: “If the misrepresentation or omission is not  
 material as to all class members, the issue of reliance ‘would vary from consumer to  
 consumer’ and the class should not be certified.” 655 F.3d at 1022-23. That is  
 precisely the case here: reliance and materiality cannot be presumed because of the  
 varying statements consumers were exposed to, and because repeat purchasers rely  
 on their own experiences.

1 exposed vary considerably. Consumers who got what they paid for or who were  
 2 never exposed to a “false” statement suffered no injury, and common questions  
 3 cannot not predominate where, as here, the class includes uninjured members.<sup>50</sup>

4 **C. Plaintiff Cannot Show Economic Injury Using Class-Wide Proof**

5 Plaintiff has also not identified any valid method for calculating the harm to  
 6 the putative class. The UCL does not grant courts authority to order the return of  
 7 arbitrary amounts of money. *Korea Supply Co. v. Lockheed Martin Corp.*, 29 Cal.  
 8 4th 1134, 1148 (2003) (“A court cannot, under … section 17203, award whatever  
 9 form of monetary relief it believes might deter unfair practices.”) Instead,  
 10 restitution is permitted only to the extent necessary to “return . . . the excess of what  
 11 the plaintiff gave the defendant over the value of what the plaintiff received.”  
 12 *Cortez v. Purolator Air Filtration Prods. Co.*, 23 Cal. 4th 163, 174 (2000), and that  
 13 restitution “must be of a measurable amount to restore to the plaintiff what has been  
 14 acquired by violations of the statutes, and that measurable amount must be  
 15 supported by evidence.” *Colgan v. Leatherman Tool Grp., Inc.*, 135 Cal. App. 4th  
 16 663, 698 (2006). Because the goal of restitution is to “return class members to  
 17 status quo, the amount of restitution due must account for the benefits received.”  
 18 *Google Adwords*, 2012 WL 28068, at \*15. See also *Yasmin*, 2012 WL 865041, at  
 19 \*21 (“in addition to showing conduct that is ‘likely to deceive,’ a party seeking  
 20 restitutionary relief [under the UCL] must establish the loss of money or property  
 21 which ‘may have been acquired’ by means of the deceptive conduct.”). See also  
 22 *Vioxx*, 180 Cal. App. 4th at 131. (“The difference between what the plaintiff paid  
 23 and the value . . . received is a proper measure of restitution. . . . In order to recover

24

25 <sup>50</sup> See *In re Yasmin*, 2012 WL 865041 at \*26; *Mazur v. eBay Inc.*, 257 F.R.D. 563,  
 26 567 (N.D. Cal. 2009) (putative class included “non-harmed” members); *In re Flash  
 27 Memory Antitrust Litig.*, 2010 WL 2332081, at \*12 (N.D. Cal. June 9, 2010)  
 28 (damages methodology “would . . . sweep in an unacceptable number of uninjured  
 plaintiffs”); *Mahfood v. QVC, Inc.*, 2008 WL 5381088, at \*4 (Sept. 22, 2008)  
 (putative class included “consumer[s] [who] could not have suffered any injury  
 from relying” on false statement).

1 under this measure, there must be evidence of the actual value ... received.”).

2 Class members who received the advertised benefits or who were not exposed  
3 to any false statements got the value they expected—as did repeat purchasers,

4 **Redacted**

(Nelson Decl. ¶¶ 22, 26.) And,

5 as discussed above, the benefits each individual receives will be affected by many  
6 factors, including genetics, lifestyle, and environment. Any valid calculation of  
7 damage or restitution will not be subject to common proof.<sup>51</sup>

8 **D. Different Class Members Were Exposed to Different Messages**

9 Where different class members were exposed to different allegedly  
10 misleading statements, courts deny certification of UCL and CLRA claims since  
11 exposure cannot be resolved on a class wide basis.<sup>52</sup> Similarly, a plaintiff alleging  
12 breach of an express warranty must show that he was exposed to the statement  
13 creating the warranty. *Moncada*, 471 F. Supp. 2d at 997; *Williams*, 185 Cal. App.  
14 3d at 142 (“one must allege the exact terms of the warranty, plaintiff’s reasonable

15

<sup>51</sup> See, e.g., *Colgan*, 135 Cal. App. 4th at 677, 700 (“although the purchasers did not  
16 receive entirely what they bargained for ... [c]lass members did benefit from the  
17 quality, usefulness, and safety of these multi-purpose tools.”); *Google Adwords*,  
18 2012 WL 28068, at \*15-\*16 (“in many instances, individual proof would show that  
advertisers received significant revenues and other benefits from ads placed on  
parked domains and error pages—benefits that would need to be individually  
19 accounted for in any restitution calculation”); *Wilens v. TD Waterhouse Grp., Inc.*,  
20 120 Cal. App. 4th 746, 756 (2003) (certification improper where “substantial and  
numerous factually unique questions ... determine ... individual right to  
recover.”); *Block v. Major League Baseball*, 65 Cal. App. 4th 538, 543 (1998)  
21 (“[e]ach [circumstance involving each plaintiff] will have to be examined for each  
class member” to determine right to recovery).

22

<sup>52</sup> See *Sevidal*, 189 Cal. App. 4th at 926, 928 (affirming denial of certification based  
23 on mislabeling of clothing as “made in the U.S.” where a majority of the class did  
not see false statements); *Cohen*, 178 Cal. App. 4th at 980 (UCL does not authorize  
24 relief “on behalf of a consumer who was never exposed in any way to an allegedly  
wrongful business practice”); *Kaldenbach v. Mut. of Omaha Life Ins. Co.*, 178 Cal.  
25 App. 4th 830, 848-49 (2009) (affirming denial of certification because of  
individualized issues as to “what materials, disclosures, representations, and  
26 explanations were given to any given purchaser.”); *Pfizer, Inc. v. Superior Court*,  
27 182 Cal. App. 4th 622 (2010); *Campion*, 272 F.R.D at 536-537 (S.D. Cal. 2011)  
28 (rejecting UCL and CLRA class where “the proposed class members may have seen  
some, all or none of these statements prior to the purchase of their home warranty  
plans due to the varying ways in which they acquired their plans”).

1 reliance thereon, and a breach ... which proximately causes plaintiff injury.”).

2 Here, there are substantial differences between the print, television, and  
 3 internet advertisements for the Rapid Wrinkle Repair products and the products’  
 4 packaging—such that many consumers will have seen only a handful of the wide  
 5 array of statements Plaintiff challenges, and the particular message (and  
 6 combination of messages) that each consumer was exposed to will vary  
 7 significantly. First, according to Plaintiff’s own allegations, *the “vast majority of*  
 8 *consumers” did not read the back of the package before buying the products.*

9 (FAC ¶ 90.) Yet most of the claims Plaintiff challenges are located *only on the*  
 10 *back* of the packages, including the statements “clinically proven,” “helps to  
 11 smooth wrinkles fast and diminish the look of age spots,” “renews the look of skin  
 12 throughout the day,” “visible results in just one week” (on RWR Eye), “fade the  
 13 look of stubborn crow’s feet,” “[b]righten and even under eye area,” “[s]mooth fine  
 14 lines and texture,” “[r]educe the look of dark circles,” and “even out skin tone.”  
 15 See (Declaration of Edward Dubendorf in Support of Mot. for Class Cert.  
 16 (“Dubendorf Decl.”), Exs. 1-6; Compl. ¶¶74-79.) Consumers who did not stop to  
 17 read the entire label were not exposed to any of those statements.<sup>53</sup>

18 Second, the challenged statements also vary substantially between products.  
 19 For example, only RWR Serum and Night include the statement “100% of women  
 20 had noticeable results.” (Dubendorf Decl. Exs. 2-3.) Unlike the three other RWR  
 21 products, the front of the box for RWR Eye only reads, “targets fine lines & crow’s  
 22 feet,” *not* “visible results in one week.” (*Id.*, Ex. 4). Charts on the back of the box  
 23 for both HSAW products explain that they “significant[ly]” “soften and smooth  
 24 skin” and “improve skin clarity” within one week, but that they take up to eight  
 25 weeks to start to “visibly reduce age spots”—statements that are not included on the  
 26 RWR boxes. (*Id.*, Exs. 5-6.) The RWR Eye box also includes statements about

27  
 28 <sup>53</sup> Some consumers likely did read the back of the box before buying. But whether  
 each consumer did so will be an important individualized issue.

1 “dark circles,” and the “under eye area” that are not on the other boxes. (*Id.*, Ex. 4.)

2 The statements in the print and television ads also varied. Only one of the  
 3 RWR print ads states that “100% of the women had noticeable results,” another  
 4 states that the products “smooth wrinkles,” another that they “visibly reduce  
 5 wrinkles,” and yet another that they “visibly reduce fine lines and wrinkles.” (Yang  
 6 Decl., Exs. 1-4.) And the internet banner ads use ***none*** of the statements Plaintiff  
 7 challenges. Instead, they simply say that the products have the “fastest retinol  
 8 formula available” (which Plaintiff does not challenge). (*Id.*, Ex. 10.) The  
 9 television ads also vary. A RWR TV ad from 2011, for example, stated that the  
 10 products have the “fastest retinol formula available” and can “smooth wrinkles in  
 11 just one week.” (*Id.*, Ex. 5.) Another ad from 2011 omits the “fastest retinol  
 12 formula available,” while a third, from 2012, states that the products can “visibly  
 13 reduce[]” wrinkles. (*Id.*, Exs. 6, 9.)

14 The different messages each consumer saw will have a huge impact on his or  
 15 her claim. For example, someone who saw an internet ad and then purchased RWR  
 16 Eye (but who did not read the back of the box) would have seen ***only*** “the fastest  
 17 retinol formula available” (in the ad) and “targets fine lines and crow’s feet” (front  
 18 of the box). (*Id.* Ex. 10; Dubendorf Decl. Ex. 4.) That consumer has no claim—  
 19 Plaintiff does not challenge the first statement, and the second cannot possibly be  
 20 actionable. Someone who saw the first print ad (or the 15-second TV ads) did not  
 21 see “the fastest retinol formula available”. (Yang Decl. Exs. 1, 6-7, 9.) And those  
 22 who bought RWR Night after seeing a TV ad (but did not read the back of the box)  
 23 never saw “100% of women had noticeable results in just one week,” or “Clinically  
 24 proven to help: fade the look of stubborn deep wrinkles, including crow’s feet  
 25 forehead & cheek wrinkles.” (*Id.*, Exs. 5-9; Dubendorf Decl. Ex. 2.) There is no  
 26 “uniform” message that can fairly substitute for the different statements to which  
 27 each consumer was exposed. Just as in *Pfizer*, *Sevidal*, *Kaldenbach*, and *Campion*,

1 that variation creates individualized issues that prevent certification.<sup>54</sup>

2       **E. An Inference of Reliance or Materiality Would Be Inappropriate**

3       To avoid the need to grapple with individualized causation questions,

4 Plaintiff argues that the Court may “infer” reliance and materiality. (Mot. at 11-

5 15.) A rebuttable inference of reliance arises as to the class **only** if Plaintiff  
6 demonstrates that the allegedly false representation was material, made to all class  
7 members, and all class members acted consistently with reliance.<sup>55</sup> But “if the issue  
8 of materiality or reliance is a matter that would vary from consumer to consumer,  
9 the issue is not subject to common proof, and the action is properly not certified as  
10 a class action.” *Vioxx*, 180 Cal. App. 4th at 129. Accordingly, “[t]he rule  
11 permitting an inference of common reliance where material misstatements have  
12 been made to a class of plaintiffs will not arise where the record will not permit it.”  
13 *Tucker*, 208 Cal. App. 4th at 228 (*citing Mass. Mut.*, 97 Cal. App. 4th at 1294).<sup>56</sup>

14       As discussed above, the evidence here precludes any class-wide inference of  
15 materiality or reliance. The different messages each consumer was exposed to, as  
16 well as the evidence that the products provide benefits to many consumers, means  
17 that class members’ claims necessarily present individualized reliance and

18       <sup>54</sup> *E.g., Pfizer*, 182 Cal. App. 4th at 631 (“one who was not exposed to the alleged  
19 misrepresentations and therefore could not possibly have lost money or property as  
20 a result of the unfair competition is not entitled to restitution”); *Campion*, 272  
21 F.R.D at 524, 536-537 (“proposed class members may have seen some, all or none  
of these statements prior to the purchase of their home warranty plans” so “reliance  
could not be inferred or established on a class-wide basis”).

22       <sup>55</sup> *See Occidental Land v. Superior Court*, 18 Cal. 3d 355, 363 (Cal. 1976)); *see also Gonzalez*, 247 F.R.D. at 624 (“[*Vasquez v. Superior Court*, 4 Cal. 3d 800 (Cal. 1971)] and its progeny only permit an inference of common reliance when the allegations demonstrate that a single, material misrepresentation was directly made to each class member.”); *Kaldenbach v. Mutual of Omaha Life Ins. Co.*, 178 Cal. App. 4th 830, 851 (rejecting inference “absent evidence of uniform material misrepresentations having been actually made to class members.”); *Campion*, 272 F.R.D at 536 (“Where a class of consumers may have seen all, some, or none of the advertisements ... an inference of common reliance or liability is not permitted”).

23       <sup>56</sup> *In re Steroid Hormone Prod. Cases*, 181 Cal. App. 4th 145 (2010), which  
24 Plaintiff cites, provides no support for an inference here. (See Mot. at 13-14.) That  
25 case simply stands for the unremarkable conclusion that consumers would consider  
26 material the fact that the product was an **illegal steroid**. 181 Cal. App. 4th at 157.

1 materiality issues.<sup>57</sup> Representations are also immaterial if consumers may have  
 2 made the same choice even without the allegedly false statement. *See, e.g., Vioxx*,  
 3 180 Cal. App. 4th at 133-34 (individual issues predominated where “*Vioxx did not*  
 4 *present ‘an increased risk of death’ compared to traditional NSAIDs for all patients*  
 5 *. . . . Some patients would still take Vioxx today if it were on the market . . . .*”).  
 6 Here, since repeat purchasers know exactly what benefits to expect, many would  
 7 clearly buy the products again no matter what was on the box. And even if reliance  
 8 could be presumed here, Neutrogena is entitled to offer class member evidence to  
 9 rebut any such inference. *E.g., Vasquez*, 4 Cal. 3d at 814 (“Defendants may, of  
 10 course, introduce evidence in rebuttal.”); *Quzada v. Loan Ctr. of Cal., Inc.*, 2009  
 11 WL 5113506, at \*5 (E.D. Cal. 2009) (presumption of reliance rebutted where  
 12 plaintiff had not read the allegedly misleading loan agreement). On these facts,  
 13 Neutrogena will be able to offer such evidence for many class members, and  
 14 individualized inquiries will be required to determine if they actually relied on any  
 15 alleged misrepresentations. *See, e.g., Granberry v. Islay Invs.*, 9 Cal. 4th 738, 751  
 16 (1995) (defense of setoff must be resolved at individual evidentiary hearings).

## 17 **VII. PLAINTIFF’S PROPOSED CLASS SUFFERS FROM A HOST OF 18 OTHER PROBLEMS**

19 First, Plaintiff must also satisfy the “implied requirement that the proposed  
 20 classes be ascertainable.”<sup>58</sup> Since the proposed classes include many uninjured

---

21 <sup>57</sup> *Campion*, 272 F.R.D at 534. (“[t]he fact the alleged misrepresentations were  
 22 made in the home warranty plans and a copy of the plan was received by every  
 23 class member does not, as Plaintiff posits, end the inquiry as to whether common  
 24 reliance should be inferred.”) *Cohen*, 178 Cal. App. 4th at 979-82 (class members  
 25 were not exposed to uniform representations and were in a “myriad of different  
 26 positions” insofar as some class members indicated that they had not been  
 27 motivated by the alleged misrepresentations); *Caro v. Proctor & Gamble Co.*, 18  
 28 Cal. App. 4th 644, 668-69 (1993) (materiality not presumed where consumers  
 differed in whether “fresh” and “no additives” labels would lead them to believe  
 orange juice was premium).

<sup>58</sup> *Gonzales v. Comcast Corp.*, 2012 WL 10621, at \*20 (E.D. Cal. Jan. 3, 2012); *see also In re Intel Corp. Microprocessor Antitrust Litig.*, 2010 WL 8591815, at \*32  
 (July 28, 2010) (“A class is overly broad if it includes members who have not  
 suffered injury. . . . If ‘[d]etermining membership in the class would essentially

1 members, they are overbroad and unascertainable.<sup>59</sup> Second, certification will  
 2 deprive Neutrogena of its right to assert individual defenses. “[C]ertification does  
 3 not serve to enlarge substantive rights or remedies.” *Feitelberg v. Credit Suisse*  
 4 *First Boston, LLC*, 134 Cal. App. 4th 997, 1014 (2006); *see also Broussard v.*  
 5 *Meineke Discount Muffler Shops, Inc.*, 155 F.3d 331, 345 (4th Cir. 1998) (“[i]t is  
 6 axiomatic that [class actions] cannot be allowed to expand the substance of the  
 7 claims of class members”). Class actions cannot be used to “deprive defendants of  
 8 their substantive rights merely because those rights are inconvenient in light of the  
 9 [class] litigation posture plaintiffs have chosen.” *Granberry*, 9 Cal. 4th at 749.  
 10 This is not a case where idiosyncratic defenses might apply to a handful of people.  
 11 Neutrogena will have real defenses<sup>60</sup> to many class members’ claims, and someone  
 12 who otherwise has no claim should not prevail just because her claim is combined  
 13 with others in a class. *City of San Jose v. Superior Court*, 12 Cal. 3d 447, 462  
 14 (1974) (“Class actions are provided only as a means to enforce substantive law.”).

15 Finally, Plaintiff has failed to prove that a class action is “superior” to other  
 16 available methods for adjudicating this controversy. *See* Fed. R. Civ. P. 23(b)(3).  
 17 Plaintiff must show that the “likely difficulties in managing a class action” can be

---

18 require a mini-hearing on the merits of each class member’s case . . . a class action  
 19 [is] inappropriate for addressing the claims at issue.”<sup>61</sup>

<sup>59</sup> *See Akkerman v. Mecta Corp.*, 152 Cal. App. 4th 1094, 1100-01 (disagreed with,  
 20 but not overruled, by *Cohen*, 178 Cal. App. 4th 966 (2009)) (plaintiff “did not show  
 21 how he could easily identify those who were deceived” and “sought restitution for  
 22 all class members without limitation . . . [which] would require a windfall award of  
 23 restitution to all who received ECT even if the procedures were successful and  
 24 beneficial.”); *Gonzales*, 2012 WL 10621, at \*20 (“A class is not ascertainable when  
 25 the proposed definition includes individuals who were never injured by the  
 26 defendant’s conduct . . .”); *Mazur*, 257 F.R.D. at 567 (class overbroad and not  
 27 ascertainable where it included unharmed individuals); *Colpinto v. Esquire*  
 28 *Deposition Servs.*, 2011 WL 913251, at \*4 (C.D. Cal. Mar. 8, 2011) (same).

<sup>60</sup> Whether a consumer was injured here will require an inquiry into a host of  
 25 individual issues that will (in many cases) tend to disprove class members’ claims.  
 26 Neutrogena will also be able to assert affirmative defenses, e.g., a repeat  
 27 purchaser’s claims would be barred (or at least reduced) on the grounds of waiver  
 28 and mitigation, as would the claims of those who received some, but not all, of the  
 promised benefits. *See, e.g., Hunter v. Croysdill*, 169 Cal. App. 2d 307, 318 (1959)  
 (mitigation); *LeClercq v. Michael*, 88 Cal. App. 2d 700, 702 (1948) (waiver).

1 overcome, *id.* at 23(b)(3)(D), an inquiry that “encompasses the whole range of  
 2 practical problems” that could make class treatment inappropriate. *Eisen v. Carlisle*  
 3 & *Jacquelin*, 417 U.S. 156, 164 (1974). Here, the the proposed class is  
 4 unmanageable and will not be the superior method of adjudicating these claims.<sup>61</sup>

### 5 **VIII. PLAINTIFF CHOW IS NOT TYPICAL OR ADEQUATE**

6 To satisfy typicality, Plaintiff must show that she is (1) part of the proposed  
 7 class, (2) possesses the same interest as the class, and (3) suffered the same injury  
 8 as the class. *Falcon*, 457 U.S. at 156. But here, her claims are not typical and she  
 9 will be subject to unique defenses that make her inadequate. *Hanon v.*  
 10 *Dataproducts Corp.*, 976 F.2d 497, 508 (9th Cir. 1992) (“certification should not be  
 11 granted if ‘there is a danger that absent class members will suffer if their  
 12 representative is preoccupied with [unique] defenses . . .’”).

13 Ms. Chow’s unusual history of skin ailments and treatments could have  
 14 masked the products’ benefits—especially the Botox injections she received while  
 15 using the products. She suffered from severe facial rashes, breakouts, and  
 16 pigmentation scars as a result of toxic mold exposure—effects that lingered for a  
 17 year after she left her contaminated apartment in 2006. (See Powers Decl. Ex. 1  
 18 (Chow Dep.) at 69:23-70:3; 70:7-71:9; 83:25-84:5; 86:11-87:2; 90:2-11.) She has  
 19 had five Botox injections since 2010, one Juvéderm injection (a gel injected into the  
 20 face) and laser skin facial treatments. She also smokes intermittently. (*Id.* at 78:21-  
 21 79:11, 91:8-103:11, 103:25-104:104:11, 118:11-19, 118:20-119:12.) Ms. Chow  
 22 also saw some benefits from more expensive retinol products—although she  
 23 claimed that the prescription Retin-A her doctor prescribed did nothing. (*Id.* at  
 24 106:10-14, 113:15-17, 106:10-109:7, 110:18-20.) If these experiences are typical,  
 25

26 <sup>61</sup> See *Zinser*, 253 F.3d at 1192 (“If each class member has to litigate numerous and  
 27 substantial separate issues to establish his or her right to recover individually, a  
 28 class action is not ‘superior’”); *Bridgestone/Firestone*, 288 F.3d at 1018 (where  
 “claims must be adjudicated under the law of so many jurisdictions, a single  
 nationwide class is not manageable.”).

1 they illustrate the individual issues that will arise in each class member's claim.

2 Ms. Chow also cannot sue over the RWR Serum because she never bought it.  
 3 It is a basic principle that a plaintiff must have standing to bring claims in federal  
 4 court, *Lujan v. Defenders of Wildlife*, 504 U.S. 555, 559-60 (1992), and Plaintiff  
 5 has no claim (under any cause of action) as to a product she never bought. *Accord*  
 6 *DaimlerChrysler Corp. v. Cuno*, 547 U.S. 332, 351-52 (2006) (standing must be  
 7 shown for every claim); *Friends of the Earth, Inc. v. Laidlaw Envtl. Servs., Inc.*,  
 8 528 U.S. 167, 181-83 (2000) (particularized injury must affect plaintiff personally).  
 9 Plaintiff cannot sue over a product she never bought, including in a class action.<sup>62</sup>

10 **IX. CONCLUSION**

11 For the foregoing reasons, Neutrogena respectfully requests that the Court  
 12 deny Plaintiff's motion in its entirety.

13 Dated: October 4, 2012

O'MELVENY & MYERS LLP

14 By:   
 15 Matthew D. Powers

16 Attorneys for Defendant  
 17 Neutrogena Corp.

18  
 19  
 20  
 21  
 22  
 23

24 <sup>62</sup> See *Larsen v. Trader Joe's Co.*, No. 3:11-cv-05188-SI, Dkt. 41 at 6 (N.D. Cal.  
 25 June 14, 2012); *Mlejnecky v. Olympus Imaging Am., Inc.*, 2011 WL 1497096, at \*4  
 26 (E.D. Cal. Apr. 19, 2011); *Carrea v. Dreyer's Grand Ice Cream, Inc.*, 2011 WL  
 27 159380, at \*3 (N.D. Cal. Jan. 10, 2011), *aff'd on other grounds*, 2012 WL 1131526  
 28 (9th Cir. Apr. 5, 2012); *Johns v. Bayer Corp.*, 2010 WL 476688, at \*5 (S.D. Cal.  
 Feb. 9, 2010) (plaintiff "cannot expand the scope of his claims to include a product  
 he did not purchase"). See also *Kwikset v. Superior Court*, 51 Cal. 4th 310, 317  
 (2011).